<SEC-DOCUMENT>0001213900-23-088524.txt : 20231120
<SEC-HEADER>0001213900-23-088524.hdr.sgml : 20231120
<ACCEPTANCE-DATETIME>20231120083011
ACCESSION NUMBER:		0001213900-23-088524
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20231120
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231120
DATE AS OF CHANGE:		20231120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40700
		FILM NUMBER:		231420803

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea188623-8k_abvcbio.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ABVC="http://abvcpharma.com/20231120">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_ABVC_abvcpharma.com_20231120 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20231120_20231120 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001173313 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:EntityCentralIndexKey">0001173313</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abvc-20231120.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-11-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-20</xbrli:startDate>
        <xbrli:endDate>2023-11-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90E_edei--DocumentType_c20231120__20231120_zqByucmQPnL9"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_904_edei--DocumentPeriodEndDate_c20231120__20231120_z3dZJLBF8Cz8"><ix:nonNumeric contextRef="AsOf2023-11-20" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 20, 2023</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20231120__20231120_zNXnxytqLFzb"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:EntityRegistrantName">ABVC BIOPHARMA, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20231120__20231120_zmeG1NYSIEwl"><ix:nonNumeric contextRef="AsOf2023-11-20" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20231120__20231120_z8b1ly4dgoH"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:EntityFileNumber">001-40700</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20231120__20231120_zdsCVCU18l52"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:EntityTaxIdentificationNumber">26-0014658</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction<br />
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer<br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20231120__20231120_zy9281pSuIk1"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:EntityAddressAddressLine1">44370 Old Warm Springs Blvd.</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressCityOrTown_c20231120__20231120_zyfdSvvZBuce"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:EntityAddressCityOrTown">Fremont</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressStateOrProvince_c20231120__20231120_zzBNvBoqmPC3"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: top; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20231120__20231120_ziCoVRCimRtg"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:EntityAddressPostalZipCode">94538</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number including area
code: <b>(<span id="xdx_905_edei--CityAreaCode_c20231120__20231120_z9GHh6j4ZaU"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:CityAreaCode">510</ix:nonNumeric></span>) <span id="xdx_901_edei--LocalPhoneNumber_c20231120__20231120_z3BQN9t4rzJe"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:LocalPhoneNumber">668-0881</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--WrittenCommunications_c20231120__20231120_zwVc7TqAaQL8"><ix:nonNumeric contextRef="AsOf2023-11-20" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--SolicitingMaterial_c20231120__20231120_zVze0Lj8tkCk"><ix:nonNumeric contextRef="AsOf2023-11-20" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementTenderOffer_c20231120__20231120_zji7Fs4OH4H3"><ix:nonNumeric contextRef="AsOf2023-11-20" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20231120__20231120_zczpeHcXudbj"><ix:nonNumeric contextRef="AsOf2023-11-20" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center; width: 2%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center; width: 2%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20231120__20231120_zUpW66AXemhi"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20231120__20231120_zeX2Bo2LyPY7"><ix:nonNumeric contextRef="AsOf2023-11-20" name="dei:TradingSymbol">ABVC</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_905_edei--SecurityExchangeName_c20231120__20231120_zeIWIYgksz9c"><ix:nonNumeric contextRef="AsOf2023-11-20" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule
12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20231120__20231120_zC6gWiJst8lj"><ix:nonNumeric contextRef="AsOf2023-11-20" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01 Entry into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 17, 2023, ABVC BioPharma, Inc. (the &#8220;<b>Company</b>&#8221;)
entered into a securities purchase agreement (the &#8220;<b>Securities Purchase Agreement</b>&#8221;) with Lind Global Fund II, LP (&#8220;<b>Lind</b>&#8221;),
pursuant to which the Company issued Lind a secured, convertible note in the principal amount of $1,200,000 (the &#8220;<b>Offering</b>&#8221;),
for a purchase price of $1,000,000 (the &#8220;<b>Note</b>&#8221;), that is convertible into shares of the Company&#8217;s common stock
at a conversion price, which shall be the lesser of (i) $3.50 (the &#8220;<b>Fixed Price</b>&#8221;) and (ii) 90% of the three lowest
VWAPs (as defined in the Note) during the 20 trading days prior to conversion (&#8220;<b>Variable Price</b>&#8221;), subject to adjustment
(the &#8220;<b>Note Shares</b>&#8221;). Notwithstanding the foregoing, provided that no Event of Default (as defined in the Note) shall
have occurred, conversions under the Note shall be at the Fixed Price for the first 180 days following the closing date. Lind will also
receive a 5-year, common stock purchase warrant (the &#8220;<b>Warrant</b>&#8221;) to purchase up to 1,000,000 shares of the Company&#8217;s
common stock at an initial exercise price of $2 per share, subject to adjustment (each, a &#8220;<b>Warrant Share</b>,&#8221; together
with the Note, Note Shares and Warrants, the &#8220;<b>Securities</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the occurrence of any Event of Default (as defined
in the Note), the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of the Note, in addition to any
other remedies under the Note or the other Transaction Documents (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Warrant may be exercised via cashless exercise
in the event a registration statement covering the Warrant Shares is not available for the resale of such Warrant Shares or upon exercise
of the Warrant in connection with a Fundamental Transaction (as defined in the Warrant).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the Securities Purchase Agreement,
if at any time prior to a date that is 18 months following the closing of the Offering, the Company proposes to offer or sell any additional
securities in a subsequent financing, the Company shall first offer Lind the opportunity to purchase up to 10% of such new securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Offering, the Company and its
subsidiaries: (i) Biokey, Inc., a California corporation (&#8220;<b>BioKey</b>&#8221;), (ii) Biolite Holding, Inc., a Nevada corporation
(&#8220;<b>BioLite</b>&#8221;), (iii) Biolite BVI, Inc., a British Virgin Islands corporation (&#8220;<b>BioLite BVI</b>&#8221;) and (iv)
American BriVision Corporation, a Delaware corporation (&#8220;<b>American BriVision</b>&#8221; and, collectively with the Company, BioKey,
BioLite, and BioLite BVI, the &#8220;<b>Guarantors</b>&#8221;), jointly and severally guaranteed all of the obligations of the Company
in connection with the Offering (the &#8220;<b>Guaranty</b>&#8221;) with certain collateral, as set forth in the related Transaction Documents
(as hereinafter defined).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The sale of the Note and the terms of the Offering,
including the Guaranty are set forth in the Securities Purchase Agreement, the Note, the Warrant, the First Amendment to Guaranty, the
First Amendment to Security Agreement, and the First Amendment to Guarantor Security Agreement (collectively, the &#8220;<b>Transaction
Documents</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Allele Capital Partners, LLC (&#8220;<b>Allele</b>&#8221;)
together with its executing broker dealer, Wilmington Capital Securities, LLC (together with its affiliates, &#8220;<b>Wilmington</b>&#8221;),
served as the exclusive placement agent (the &#8220;<b>Placement Agent</b>&#8221;) of the Offering. We have agreed to pay certain expenses
of the placement agent in connection with the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Securities Purchase Agreement
also contains customary representation and warranties of the Company and the Investors, indemnification obligations of the Company, termination
provisions, and other obligations and rights of the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing description of the Transaction Documents
is qualified by reference to the full text of the forms of the Transaction Documents, which are filed as Exhibits hereto and incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Neither this Current Report on Form 8-K, nor any
exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure
does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company&#8217;s securities
in any state in which such offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under
the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable
exemption from the registration requirements under the Securities Act and applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information contained above under Item 1.01,
to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of Lind in the Securities
Purchase Agreement, the offering and sale of the Securities was made in reliance on the exemption afforded by Section 4(a)(2) of the
Securities Act and Rule 506 of Regulation D under the Securities Act and corresponding provisions of state securities or &#8220;blue
sky&#8221; laws. None of the Securities have been registered under the Securities Act or any state securities laws and may not be offered
or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. The sale
of the Securities did not involve a public offering and was made without general solicitation or general advertising. The Company relied
on this exemption from registration based in part on representations made by Lind.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt">(d)
<i>Exhibits.</i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 9%"><span style="font-size: 10pt">Exhibit <br />
Number</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 90%"><span style="font-size: 10pt">Exhibit</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.1</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea188623ex10-1_abvcbio.htm"><span style="font-size: 10pt">Securities Purchase Agreement</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.2</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea188623ex10-2_abvcbio.htm"><span style="font-size: 10pt">Form of Note</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.3</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt"><a href="ea188623ex10-3_abvcbio.htm">Form of Warrant</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.4</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea188623ex10-4_abvcbio.htm"><span style="font-size: 10pt">First Amendment To Security Agreement</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.5</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea188623ex10-5_abvcbio.htm"><span style="font-size: 10pt">First Amendment To Guarantor Security Agreement</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">10.6</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea188623ex10-6_abvcbio.htm"><span style="font-size: 10pt">First Amendment to Guaranty</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">104</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>ABVC BioPharma, Inc.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 70%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 20, 2023</p></td>
    <td style="width: 5%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 25%">&#160;/s/ Uttam Patil</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>














</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Wsof8sLLpCKyCJHodskplnRHZlfLR+otW5VoGBiGc75zhPDFjraqRobrusihxKatpUUo8I6M+obOke0PKbhb4EMZy1Lb6f2BGTkGHbNaRIF0wmTtlcEqhTBchskyiiFI0ngF56PwRj0jfVcVaqtkDVJXcGZqWaGVPMwJpXyTpmaYqi7IRpF2cYtglj8QBWEEJ+rli/hpIM8z4fnTeGLH1LVjTWcsNbCpsXFdZkb/630BGBBJSg== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea188623ex10-1_abvcbio.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(as amended, supplemented, restated and/or modified from time to time, this &ldquo;<B>Agreement</B>&rdquo;) is entered into as of November
17, 2023, by and between ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Lind Global Fund II LP, a
Delaware limited partnership (the &ldquo;<B>Investor</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BACKGROUND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A. The
board of directors (the &ldquo;<B>Board of Directors</B>&rdquo;) of the Company has authorized the issuance to Investor of the Note (as
defined below) and the Warrant (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B The
Investor desires to purchase the Note and the Warrant on the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW THEREFORE, in consideration
of the foregoing recitals and the covenants and agreements set forth herein, and intending hereby to be legally bound, the Company and
the Investor hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase">1. </FONT><B><U>DEFINITIONS</U></B>.
As used in this Agreement, the following terms shall have the following meanings specified or indicated below, and such meanings shall
be equally applicable to the singular and plural forms of such defined terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>1933 Act</B>&rdquo;
means the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>1934 Act</B>&rdquo;
means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Acquisition</B>&rdquo;
means the acquisition by the Company or any direct or indirect Subsidiary of the Company of a majority of the Equity Interests or substantially
all of the assets and business of any Person, whether by direct purchase of Equity Interests, asset purchase, merger, consolidation or
like combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control
with, the Person specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Blue Sky Application</B>&rdquo;
has the meaning set forth in <U>Section 9.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Board of Directors</B>&rdquo;
has the meaning set forth in the recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
means any day other than a Saturday, Sunday or any other day on which banks are permitted or required to be closed in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Capital Stock</B>&rdquo;
means the Common Stock and any other classes of capital stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Change of Control</B>&rdquo;
means, with respect to the Company, on or after the date of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 34.9pt">(a)</TD><TD STYLE="text-align: justify">a change in the composition of the Board of Directors of the Company at a single shareholder meeting where
a majority of the individuals that were directors of the Company immediately prior to the start of such shareholder meeting are no longer
directors at the conclusion of such meeting, without prior written consent of the Investor;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">a change, without prior written consent of the Investor, in the composition of the Board of Directors
of the Company prior to the termination of this Agreement where a majority of the individuals that were directors as of the date of this
Agreement cease to be directors of the Company prior to the termination of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">other than a shareholder that holds such a position at the date of this Agreement, if a Person comes to
have beneficial ownership, control or direction over more than thirty-three percent (33%) of the voting rights attached to any class of
voting securities of the Company; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">the sale or other disposition by the Company or any of its Subsidiaries in a single transaction, or in
a series of transactions, of all or substantially all of their respective assets.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing</B>&rdquo;
has the meaning set forth in <U>Section 2.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing Date</B>&rdquo;
has the meaning set forth in <U>Section 2.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commitment Fee</B>&rdquo;
means an amount equal to Three- and One-Half Percent (3.5%) of the applicable Funding Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common Stock</B>&rdquo;
means the common stock of the Company, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company</B>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Conversion Shares</B>&rdquo;
means the Common Stock issuable upon the full or any partial conversion of the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disclosure Letter</B>&rdquo;
has the meaning set forth in <U>Section 3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Effectiveness Period</B>&rdquo;
has the meaning set forth in <U>Section 9.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Equity Interests</B>&rdquo;
means and includes capital stock, membership interests and other similar equity securities, and shall also include warrants or options
to purchase capital stock, membership interests or other equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Event</B>&rdquo;
means any event, change, development, effect, condition, circumstance, matter, occurrence or state of facts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Event of Default</B>&rdquo;
has the meaning set forth in <U>Section 7.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exempted Securities</B>&rdquo;
means (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly
adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee
of non-employee directors established for such purpose for services rendered to the Company (&ldquo;<B>Equity Plan</B>&rdquo;), (b) securities
issued upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have
not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange
price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such
securities, or (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors
of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no
registration rights that require or permit the filing of any registration statement in connection therewith, and provided that any such
issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company
or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits
in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the
purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Form 8-K&rdquo;</B>
has the meaning set forth in <U>Section 5.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Funding Amount&rdquo;</B>
means an amount equal to One Million Dollars ($1,000,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GAAP</B>&rdquo;
means United States generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>HSR Act</B>&rdquo;
has the meaning set forth in <U>Section 5.15</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor</B>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor Group</B>&rdquo;
shall mean the Investor plus any other Person with which the Investor is considered to be part of a group under Section 13 of the 1934
Act or with which the Investor otherwise files reports under Sections 13 and/or 16 of the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor Party</B>&rdquo;
has the meaning set forth in <U>Section 5.11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor Shares</B>&rdquo;
means the Conversion Shares, the Warrant Shares and any other shares issued or issuable to the Investor pursuant to this Agreement, Note
or the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IP Rights</B>&rdquo;
has the meaning set forth in <U>Section 3.10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Law</B>&rdquo; means
any law, rule, regulation, order, judgment or decree, including, without limitation, any federal and state securities Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Legend Removal Date</B>&rdquo;
shall have the meaning set forth in <U>Section 5.1(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Losses</B>&rdquo;
has the meaning set forth in <U>Section 5.9(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Material Adverse
Effect</B>&rdquo; means any material adverse effect on (i) the businesses, properties, assets, prospects, operations, results of operations
or financial condition of the Company, or the Company and the Subsidiaries, taken as a whole, or (ii) the ability of the Company to consummate
the transactions contemplated by this Agreement or to perform its obligations hereunder or under the Note or the Warrant; <I>provided,
however</I>, that none of the following shall be deemed either alone or in combination to constitute, and none of the following shall
be taken into account in determining whether there has been or would be, a Material Adverse Effect: (a)&nbsp;any adverse effect resulting
from or arising out of general economic conditions; (b) any adverse effect resulting from or arising out of general conditions in the
industries in which the Company and the Subsidiaries operate; (c) any adverse effect resulting from any changes to applicable Law; or
(d)&nbsp;any adverse effect resulting from or arising out of any natural disaster or any acts of terrorism, sabotage, military action
or war or any escalation or worsening thereof; <I>provided</I>, <I>further</I>, that any event, occurrence, fact, condition or change
referred to in clauses (a) through (d) immediately above shall be taken into account in determining whether a Material Adverse Effect
has occurred or could reasonably be expected to occur to the extent that such event, occurrence, fact, condition or change has a disproportionate
effect on the Company and/or the Subsidiaries compared to other participants in the industries in which the Company and the Subsidiaries
operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Maximum Percentage</B>&rdquo;
means 4.99%; <I>provided</I>, that if at any time after the date hereof the Investor Group beneficially owns in excess of 4.99% of any
class of Equity Interests in the Company that is registered under the 1934 Act, then the Maximum Percentage shall automatically increase
to 9.99% so long as the Investor Group owns in excess of 4.99% of such class of Equity Interests (and shall, for the avoidance of doubt,
automatically decrease to 4.99% upon the Investor Group ceasing to own in excess of 4.99% of such class of Equity Interests).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Money Laundering
Laws</B>&rdquo; has the meaning set forth in <U>Section 3.25</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>New Securities</B>&rdquo;
means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to
purchase such equity securities, or securities of any type whatsoever that are, or may become convertible or exchangeable into or exercisable
for such equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Note</B>&rdquo;
has the meaning set forth in <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Notice Termination
Time&rdquo;</B> has the meaning set forth in <U>Section 10.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>OFAC</B>&rdquo;
has the meaning set forth in <U>Section 3.23</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Offer Notice</B>&rdquo;
has the meaning set forth in <U>Section 10.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment Amount</B>&rdquo;
means an amount in cash equal to five percent (5%) of the Outstanding Principal Amount set forth in a Prepayment Notice delivered to the
Investor pursuant to <U>Section 1.4</U> of the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment Notice</B>&rdquo;
has the meaning set forth in <U>Section 1.4</U> of the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment Right</B>&rdquo;
has the meaning set forth in <U>Section 2.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment Right
Date</B>&rdquo; means sixty (60) days following such date as Conversion Shares and the Warrant Shares, may be offered or sold pursuant
to an effective Registration Statement or in a transaction not subject to the registration requirements of the Securities Act and in accordance
with applicable State securities laws as evidenced by a legal opinion of counsel to the Company to such effect the substance of which
shall be reasonably acceptable to the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Press Release&rdquo;</B>
has the meaning set forth in <U>Section 5.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Principal Amount</B>&rdquo;
has the meaning set forth in <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Proceedings</B>&rdquo;
has the meaning set forth in <U>Section 3.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prohibited Transaction</B>&rdquo;
means a transaction with a third party or third parties in which the Company issues or sells (or arranges or agrees to issue or sell):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) any
debt, equity or equity-linked securities (including options or warrants) that are convertible into, exchangeable or exercisable for, or
include the right to receive shares of the Company&rsquo;s Capital Stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) at
a conversion, repayment, exercise or exchange rate or other price that is based on, and/or varies with, a discount to the future trading
prices of, or quotations for, shares of Common Stock; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) at
a conversion, repayment, exercise or exchange rate or other price that is subject to being reset at some future date after the initial
issuance of such debt, equity or equity-linked security or upon the occurrence of specified or contingent events (other than warrants
that may be repriced by the Company); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) any
securities in a capital or debt raising transaction or series of related transactions which grant to an investor the right to receive
additional securities based upon future transactions of the Company on terms more favorable than those granted to such investor in such
first transaction or series of related transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and are deemed to include transactions generally
referred to as at-the-market transactions (ATMs) or equity lines of credit and stand-by equity distribution agreements, and convertible
securities and loans having a similar effect. Notwithstanding the foregoing, and for the avoidance of doubt, rights issuances, shareholder
purchase plans, Equity Plans, or Common Stock Shares on the Trading Market but each at a fixed price per share, shall not be deemed to
be a Prohibited Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prospectus</B>&rdquo;
means the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with respect to
the terms of the offering of any portion of the Investor Shares covered by such Registration Statement and by all other amendments and
supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus, and
any &ldquo;free writing prospectus&rdquo; as defined in Rule 405 under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>register</B>,&rdquo;
&ldquo;<B>registered</B>&rdquo; and &ldquo;<B>registration</B>&rdquo; refer to a registration made by preparing and filing a Registration
Statement or similar document in compliance with the 1933 Act (as defined below), and the declaration or ordering of effectiveness of
such Registration Statement or document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registration Statement</B>&rdquo;
means any registration statement of the Company filed under the 1933 Act that covers the resale of any of the Investor Shares pursuant
to the provisions of this Agreement, including the Prospectus and amendments and supplements to such Registration Statement, and including
post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Required Minimum</B>&rdquo;
means, as of any date, 200% of the maximum aggregate number of shares of Common Stock then issued or potentially issuable in the future
pursuant to the Transaction Documents, including any Warrant Shares issuable upon exercise in full of the Warrant or Conversion Shares
issuable upon conversion in full of the Note, ignoring any conversion or exercise limits set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SEC</B>&rdquo; means
the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SEC Documents</B>&rdquo;
has the meaning set forth in <U>Section 3.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities</B>&rdquo;
means the Note, the Warrant and the Investor Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities Termination
Event</B>&rdquo; means either of the following has occurred:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) trading
in securities generally in the United States has been suspended or limited for a consecutive period of greater than three (3) Business
Days; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) a
banking moratorium has been declared by the United States or the New York State authorities and is continuing for a consecutive period
of greater than three (3) Business Days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Security Agreement</B>&rdquo;
means the Security Agreement dated February 23, 2023 issued by the Company in favor of the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Shareholder Approval</B>&rdquo;
shall mean the approval of the holders of a majority of the Company&rsquo;s outstanding voting Common Stock: (a) if and to the extent
legally required, to amend the Company&rsquo;s Articles of Incorporation to increase the number of authorized shares of Common Stock by
at least the number of shares equal to the number of shares of Common Stock issuable under the Transaction Documents, or (b) to ratify
and approve all of the transactions contemplated by the Transaction Documents, including the issuance of all of the Investor Shares (as
such term is defined in each of such documents) issued and potentially issuable to the Investor thereunder, all as may be required by
the applicable rules and regulations of the Trading Market (or any successor entity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsequent Financing</B>&rdquo;
has the meaning set forth in <U>Section 10.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsidiaries</B>&rdquo;
and &ldquo;<B>Subsidiary</B>&rdquo; have the meaning set forth in <U>Section 3.4(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsidiary Guarantee</B>&rdquo;
means a Subsidiary Guarantee dated February 23, 2023 issued in favor of the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Trading Day&rdquo;</B>
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading Market</B>&rdquo;
means whichever of the New York Stock Exchange, NYSE American, or the Nasdaq Stock Market (including the Nasdaq Capital Market), on which
the Common Stock is listed or quoted for trading on the date in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transaction Documents</B>&rdquo;
means this Agreement, the Note, the Warrant, the Security Agreement (as amended), the Subsidiary Guarantee (as amended), the Transfer
Agent Instruction Letter and any other documents or agreements executed or delivered in connection with the transactions contemplated
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer Agent</B>&rdquo;
shall mean Vstock Transfer, LLC having its address at 18 Lafayette Place, Woodmere, NY 11598,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer Agent Instruction
Letter</B>&rdquo; shall mean a letter of irrevocable instructions addressed by the Company to the Transfer Agent, acceptable to the Investor
in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>VWAP&rdquo;</B>
means, as of any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of one share of Common Stock trading in the ordinary course of
business at the applicable Trading Price for such date (or the nearest preceding date) on such Trading Market as reported by Bloomberg
Financial L.P.; (b) if the Common Stock is not then listed on a Trading Market and if the Common Stock traded in the over-the-counter
market, as reported by the OTCQX or OTCQB Markets, the volume weighted average price of one share of Common Stock for such date (or the
nearest preceding date) on the OTCQX or OTCQB Markets, as reported by Bloomberg Financial L.P.; (c) if the Common Stock is not then listed
or quoted on a Trading Market or on the OTCQX or OTCQB Markets and if prices for the Common Stock are then reported in the &ldquo;Pink
Sheets&rdquo; published by the OTC Markets Group (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price of one share of Common Stock so reported, as reported by Bloomberg Financial L.P.; or (d) in all other cases,
the fair market value of one share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and
reasonably acceptable to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Warrant&rdquo;</B>
has the meaning set forth in <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Warrant Shares</B>&rdquo;
means the shares of Common Stock issuable upon exercise of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>2.
</B></FONT><B><U>PURCHASE AND SALE OF THE NOTE AND THE WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.1 </B></FONT><U>Purchase
and Sale of the Note and the Warrant</U>. Subject to the terms and conditions set forth herein at the Closing, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Company shall issue and sell to </FONT>the <FONT STYLE="font-family: Times New Roman, Times, Serif">Investor, and </FONT>the <FONT STYLE="font-family: Times New Roman, Times, Serif">Investor
shall purchase from the Company, for the Funding Amount </FONT>(a) <FONT STYLE="font-family: Times New Roman, Times, Serif">a </FONT>convertible
promissory note, in the form attached hereto as <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exhibit </U></FONT><U><B>A</B></U>
(the <B>&ldquo;Note</B>&rdquo;), <FONT STYLE="font-family: Times New Roman, Times, Serif">in the principal amount of One Million Two Hundred
Thousand Dollars </FONT>($1,200,000) (the <B>&ldquo;Principal Amount</B>&rdquo;) and (b) a Common Stock purchase warrant, in the form
attached hereto as <B><U>Exhibit B</U></B>, registered in the name of the Investor, pursuant to which the Investor shall have the right
to acquire [1,000,000] shares of Common Stock (the <B>&ldquo;Warrant&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.2 </B></FONT><U>Closing</U>.
The closing of the offer and sale of the Note and the Warrant shall take place remotely via the exchange of documents and signature and
shall occur no later than ten (10) Business Days following the execution and delivery of this Agreement, subject to satisfaction or waiver
of the conditions set forth in <U>Section 6</U>, or at such other time and place as the Company and the Investor agree upon, orally or
in writing (the &ldquo;<B>Closing</B>&rdquo;, and the date the Closing is completed being the <B>&ldquo;Closing Date&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.3 </B></FONT><U>Commitment
Fee</U>. At the Closing, the Company shall pay to the Investor the Commitment Fee, in United States dollars and in immediately available
funds. The Commitment Fee shall be paid by being offset against the applicable Funding Amount payable by the Investor at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.4 </B></FONT><U>Prepayment
Right.</U> As set forth in the Note, at any time following the Prepayment Right Date and upon giving the prior written notice set forth
in the Note , the Company will have the right to pre-pay the entire then-outstanding principal amount of the Note at any time (the &ldquo;<B>Prepayment
Right</B>&rdquo;); <I>provided</I>, that in the event that the Company elects to exercise its Prepayment Right, the Investor will have
the option to convert up to one-third (1/3) of the Principal Amount of the Note, at a price per share equal to the lesser of the Repayment
Share Price or the Conversion Price (as each such term is defined in the Note).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.5 </B></FONT><U>Senior
Obligation</U>. As an inducement for the Investor to enter into this Agreement and to purchase the Note, all obligations of the Company
pursuant to this Agreement and the Note shall be senior to all other existing Indebtedness and equity of the Company. Upon any Liquidation
Event (as defined in the Note), the Investor will be entitled to receive, before any distribution or payment is made upon, or set apart
with respect to, any Indebtedness of the Company or any class of capital stock of the Company, an amount equal to the Outstanding Principal
Amount (as defined in the Note).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>3.
</B></FONT><B><U>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</U></B>. The Company represents and warrants to the Investor and covenants
with the Investor that as of the Closing Date, except as is set forth in the Disclosure Letter being delivered to the Investor as of
the date hereof and updated and delivered to the Investor as of the Second Closing Date, as applicable (the <B>&ldquo;Disclosure Letter&rdquo;</B>),
the following representations and warranties are true and correct:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.1
</B></FONT><U>Organization and Qualification</U>. The Company is a corporation duly organized and validly existing in good standing under
the Laws of the State of Nevada and has the requisite corporate power and authority to own its properties and to carry on its business
as now being conducted. The Company is duly qualified to do business and is in good standing (if a good standing concept exists in such
jurisdiction) in every jurisdiction in which the ownership of its property or the nature of the business conducted by it makes such qualification
necessary, except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.2
</B></FONT><U>Authorization; Enforcement; Compliance with Other Instruments</U>. The Company has the requisite corporate power and authority
to execute the Transaction Documents, to issue and sell the Note and the Warrant pursuant hereto, and to perform its obligations under
the Transaction Documents, including issuing the Investor Shares on the terms set forth in this Agreement. The execution and delivery
of the Transaction Documents by the Company and the issuance and sale of the Securities pursuant hereto, including without limitation
the reservation of the Conversion Shares and the Warrant Shares for future insuance, have been duly and validly authorized by the Company&rsquo;s
Board of Directors and no further consent or authorization is required by the Company, its Board of Directors, its shareholders or any
other Person in connection therewith. The Transaction Documents have been duly and validly executed and delivered by the Company and
constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except
as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar Laws relating to, or affecting generally, the enforcement of creditors&rsquo; rights and remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.3
</B></FONT><U>No Conflicts</U>. The execution, delivery and performance of the Transaction Documents by the Company and the issuance
and sale of the Note and the Warrant hereunder will not (a) conflict with or result in a violation of the Company&rsquo;s Articles of
Incorporation or Bylaws, (b)&nbsp;conflict with, or constitute a material default (or an event which, with notice or lapse of time or
both, would become a material default) under, or give to others any right of termination, amendment, acceleration or cancellation of,
any material agreement to which the Company or any of the Subsidiaries is a party, or (c) subject to the making of the filings referred
to in <U>Section&nbsp; 5</U>, violate in any material respect any Law or any rule or regulation of the Trading Market applicable to the
Company or any of the Subsidiaries or by which any of their properties or assets are bound or affected. Assuming the accuracy of the
Investor&rsquo;s representations in <U>Section&nbsp;4</U> and subject to the making of the filings referred to in <U>Section&nbsp;5</U>,
(i) no approval or authorization will be required from any governmental authority or agency, regulatory or self-regulatory agency or
other third party (including the Trading Market) in connection with the issuance of the Note and the Warrant and the other transactions
contemplated by this Agreement (including the issuance of the Conversion Shares upon conversion of the Note and the Warrant Shares upon
the exercise of the Warrant) and (ii)&nbsp;the issuance of the Note and the Warrant, and the issuance of the Conversion Shares upon the
conversion of the Note and the Warrant Shares upon exercise of the Warrant will be exempt from the registration and qualification requirements
under the 1933 Act and all applicable state securities Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.4
</B></FONT><U>Capitalization and Subsidiaries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) </FONT>The
authorized Capital Stock of the Company consists of 10,000,000 shares of Common Stock. As of the close of business on December 31, 2022,
3,285,733 shares of Common Stock were issued and outstanding; and since December 31, 2022, and through the date of this Agreement, the
Company has issued 22,341 additional shares of Common Stock. As of December 31, 2022, (i) an aggregate of 2,979,624 shares of Common Stock
are issuable upon exercise of options granted under the Amended and Restated 2016 Equity Incentive Plan, of which 2,587,104 shares were
exercisable as of December 31, 2022, and 392,160 additional shares are reserved for future issuance thereunder and (ii) 32,952 shares
of Common Stock are reserved for issuance upon exercise of outstanding warrants with exercise prices ranging from $2 to $3 per share.
The Company has duly reserved up to 705,557 shares of Common Stock for issuance upon conversion of the Note and has duly reserved up to
1,058,333 shares of Common Stock for issuance upon exercise of the Warrant. The Conversion Shares, when issued upon conversion of the
Note in accordance with their terms, and the Warrant Shares, if and when issued upon exercise of the Warrant in accordance with their
terms, will be validly issued, fully paid and non-assessable and free from all taxes, liens and charges with respect to the issuance thereof.
No shares of the Company&rsquo;s Capital Stock are subject to preemptive rights or any other similar rights or any liens or encumbrances
suffered or permitted by the Company. The Company&rsquo;s Articles of Incorporation and Bylaws on file on the SEC&rsquo;s EDGAR website
are true and correct copies of the Company&rsquo;s Articles of Incorporation and Bylaws as in effect as of the <FONT STYLE="font-family: Times New Roman, Times, Serif">Closing
Date. The Company is not in violation of any provision of its Articles</FONT> of <FONT STYLE="font-family: Times New Roman, Times, Serif">Incorporation
or Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b) </FONT><U>Schedule
3.4(b)</U> lists each direct and indirect subsidiary of the Company (each, a &ldquo;<B>Subsidiary</B>&rdquo; and collectively, the &ldquo;<B>Subsidiaries</B>&rdquo;).
The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary. No Subsidiary has any
outstanding stock options, warrants or other instruments pursuant to which such Subsidiary may at any time or under any circumstances
be obligated to issue any shares of its capital stock or other Equity Interests. Each Subsidiary is duly organized and validly existing
in good standing under the laws of its jurisdiction of formation (if a good standing concept exists in such jurisdiction) and has all
requisite power and authority to own its properties and to carry on its business as now being conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) Neither
the Company nor any Subsidiary is bound by any agreement or arrangement pursuant to which it is obligated to register the sale of any
securities under the 1933 Act. There are no outstanding securities of the Company or any of the Subsidiaries which contain any redemption
or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary
is or may become bound to redeem or purchase any security of the Company or any Subsidiary. There are no outstanding securities or instruments
containing anti-dilution or similar provisions that will be triggered by the issuance of the Note, the Warrant or the Investor Shares.
Neither the Company nor any Subsidiary has any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) The
issuance and sale of any of the Securities will not obligate the Company to issue shares of Common Stock or other securities, or to satisfy
any related contractual obligations, to any other Person and will not result in the adjustment of the exercise, conversion, exchange,
or reset price of any outstanding securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(e) </FONT>As
of the date of this Agreement, the Company has capacity under the rules and regulations of the Trading Market to issue up to 1,446,388
shares of Common Stock (or securities convertible into or exercisable for shares of Common Stock) without obtaining Shareholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.5
</B></FONT><U>SEC Documents; Financial Statements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a) </FONT>As
of the <FONT STYLE="font-family: Times New Roman, Times, Serif">Closing Date</FONT>, the Company has filed all reports, schedules, forms,
statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act for the
two years preceding the <FONT STYLE="font-family: Times New Roman, Times, Serif">Closing Date</FONT> (or such shorter period as the Company
was required by law or regulation to file such material) (all of the foregoing filed prior to the <FONT STYLE="font-family: Times New Roman, Times, Serif">Closing
Date </FONT>and all exhibits included therein and financial statements and schedules thereto and documents incorporated by reference therein
being hereinafter referred to as the &ldquo;<B>SEC Documents</B>&rdquo;). As of their respective filing dates, the SEC Documents complied
in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable
to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b) </FONT>As
of their respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all material respects
with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements
have been prepared in accordance with International Financial Reporting Standards, and audited by a firm that is a member a member of
the Public Companies Accounting Oversight Board consistently applied, during the periods involved (except as may be otherwise indicated
in such financial statements or the notes thereto, or, in the case of unaudited interim statements, to the extent they may exclude footnotes
or may be condensed or summary statements) and fairly present in all material respects the consolidated financial position of the Company
as of the dates thereof and the consolidated results of its operations and consolidated cash flows for the periods then ended (subject,
in the case of unaudited statements, to normal year-end audit adjustments). No other written information provided by or on behalf of the
Company to the Investor in connection with the Investor&rsquo;s purchase of the Note and the Warrant which is not included in the SEC
Documents contains any untrue statement of a material fact or omits to state any material fact necessary to make the statements therein,
in the light of the circumstance under which they are or were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c) </FONT>The
Company and each of the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) reasonable
controls to safeguard assets are in place and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.6
</B></FONT><U>Litigation and Regulatory Proceedings</U>. There are no material actions, causes of action, suits, claims, proceedings,
inquiries or investigations (collectively, &ldquo;<B>Proceedings</B>&rdquo;) before or by any court, public board, government agency,
self-regulatory organization or body pending or, to the knowledge of the executive officers of Company or any of the Subsidiaries, threatened
against or affecting the Company or any of the Subsidiaries, the Common Stock or any other class of issued and outstanding shares of
the Company&rsquo;s Capital Stock, or any of the Company&rsquo;s or the Subsidiaries&rsquo; officers or directors in their capacities
as such and, to the knowledge of the executive officers of the Company, there is no reason to believe that there is any basis for any
such Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.7
</B></FONT><U>No Undisclosed Events, Liabilities or Developments</U>. No event, development or circumstance has occurred or exists, or
to the knowledge of the executive officers of the Company is reasonably anticipated to occur or exist that (a) would reasonably be anticipated
to have a Material Adverse Effect or (b) would be required to be disclosed by the Company under applicable securities Laws on a registration
statement filed with the SEC relating to an issuance and sale by the Company of its Common Stock and which has not been publicly announced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.8
</B></FONT><U>Compliance with Law</U>. The Company and each of the Subsidiaries have conducted and are conducting their respective businesses
in compliance in all material respects with all applicable Laws and are in compliance in all material respects with the rules and regulations
of the Trading Market. Except as set forth on Schedule 3.8, the Company is not aware of any facts which could reasonably be anticipated
to lead to have the effect of, delisting the Common Stock from the Trading Market, nor has the Company received any notification that
the Trading Market is currently contemplating terminating such listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.9
</B></FONT><U>Employee Relations</U>. Neither the Company nor any Subsidiary is involved in any union labor dispute nor, to the knowledge
of the Company, is any such dispute threatened. Neither the Company nor any Subsidiary is a party to any collective bargaining agreement.
No executive officer (as defined in Rule 501(f) of the 1933 Act) has notified the Company that such officer intends to leave the Company&rsquo;s
employ or otherwise terminate such officer&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.10
</B></FONT><U>Intellectual Property Rights</U>. The Company and each Subsidiary owns or possesses adequate rights or licenses to use
all trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights (collectively, &ldquo;<B>IP Rights</B>&rdquo;)
necessary to conduct their respective businesses as now conducted. None of the material IP Rights of the Company or any of the Subsidiaries
are expected to expire or terminate within three (3) years from the date of this Agreement. Neither the Company nor any Subsidiary is
infringing, misappropriating or otherwise violating any IP Rights of any other Person. No claim has been asserted, and no Proceeding
is pending, against the Company or any Subsidiary alleging that the Company or any Subsidiary is infringing, misappropriating or otherwise
violating the IP Rights of any other Person, and, to the Company&rsquo;s knowledge, no such claim or Proceeding is threatened, and the
Company is not aware of any facts or circumstances which might give rise to any such claim or Proceeding. The Company and the Subsidiaries
have taken commercially reasonable security measures to protect the secrecy, confidentiality and value of all of their material IP Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.11
</B></FONT><U>Environmental Laws</U>. Except, in each case, as would not be reasonably anticipated to have a Material Adverse Effect,
the Company and the Subsidiaries (a) are in compliance with any and all applicable Laws relating to the protection of human health and
safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants, (b) have received and hold all permits,
licenses or other approvals required of them under all such Laws to conduct their respective businesses and (c) are in compliance with
all terms and conditions of any such permit, license or approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.12
</B></FONT><U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title to all personal property owned by
them which is material to their respective businesses, in each case free and clear of all liens, encumbrances and defects. Any real property
and facilities held under lease by the Company or any Subsidiary are held under valid, subsisting and enforceable leases with such exceptions
as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and
the Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.13
</B></FONT><U>Insurance</U>. The Company and each of the Subsidiaries are insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as management of the Company reasonably believes to be prudent and customary in the
businesses in which the Company and the Subsidiaries are engaged. Neither the Company nor any of the Subsidiaries has been refused any
insurance coverage sought or applied for, and the Company has no reason to believe that it will not be able to renew all existing insurance
coverage as and when such coverage expires or to obtain similar coverage from similar insurers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.14
</B></FONT><U>Regulatory Permits</U>. The Company and the Subsidiaries have in full force and effect all certificates, approvals, authorizations
and permits from all regulatory authorities and agencies necessary to own, lease or operate their respective properties and assets and
conduct their respective businesses, and neither the Company nor any Subsidiary has received any notice of Proceedings relating to the
revocation or modification of any such certificate, approval, authorization or permit, except for such certificates, approvals, authorizations
or permits with respect to which the failure to hold would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.15
</B></FONT><U>No Materially Adverse Contracts, Etc</U>. Neither the Company nor any of the Subsidiaries is (a) subject to any charter,
corporate or other legal restriction, or any judgment, decree or order which in the judgment of the Company&rsquo;s officers has or is
expected in the future to have a Material Adverse Effect or (b) a party to any contract or agreement which in the judgment of the Company&rsquo;s
management has or would reasonably be anticipated to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.16
</B></FONT><U>Taxes</U>. The Company and the Subsidiaries each has made or filed, or caused to be made or filed, all United States federal
and other material tax returns, reports and declarations required by any jurisdiction to which it is subject and has paid all taxes and
other governmental assessments and charges that are material in amount, required to be paid by it, regardless of whether such amounts
are shown or determined to be due on such returns, reports and declarations, except those being contested in good faith by appropriate
proceedings and for which it has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent
to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due
by the taxing authority of any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.17 </B></FONT><U>Solvency</U>.
After giving effect to the receipt by the Company of the proceeds from the transactions contemplated by this Agreement (a) the Company&rsquo;s
fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing
debts and other liabilities (including known contingent liabilities) as they mature; and (b)&nbsp;the current cash flow of the Company,
together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated
uses of the cash, would be sufficient to pay all amounts on or in respect of its debt when such amounts are required to be paid. The Company
does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash
to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that
it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.18 </B></FONT><U>Investment
Company</U>. The Company is not, and is not an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment
Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.19
</B></FONT><U>Certain Transactions</U>. Other than as disclosed in the SEC Documents, there are no contracts, transactions, arrangements
or understandings between the Company or any of its Subsidiaries, on the one hand, and any director, officer or employee thereof on the
other hand, that would be required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC in the Company&rsquo;s
Form 10-K or proxy statement pertaining to an annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.20
</B></FONT><U>No General Solicitation</U>. Neither the Company, nor any of its Affiliates, nor any person acting on its behalf, has engaged
in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale
of the Note or the Warrant pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.21
</B></FONT><U>Acknowledgment Regarding the Investor&rsquo;s Purchase of the Note and the Warrant</U>. The Company&rsquo;s Board of Directors
has approved the execution of the Transaction Documents and the issuance and sale of the Note and the Warrant, based on its own independent
evaluation and determination that the terms of the Transaction Documents are reasonable and fair to the Company and in the best interests
of the Company and its stockholders. The Company is entering into this Agreement and is issuing and selling each of the Note and the
Warrant voluntarily and without economic duress. The Company has had independent legal counsel of its own choosing review the Transaction
Documents and advise the Company with respect thereto. The Company acknowledges and agrees that the Investor is acting solely in the
capacity of an arm&rsquo;s length purchaser with respect to the Note and the Warrant and the transactions contemplated hereby and that
neither the Investor nor any person affiliated with the Investor is acting as a financial advisor to, or a fiduciary of, the Company
(or in any similar capacity) with respect to execution of the Transaction Documents or the issuance of the Note and the Warrant or any
other transaction contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>3.22
</B></FONT><U>No Brokers&rsquo;, Finders&rsquo; or Other Advisory Fees or Commissions</U>. Except as set forth on Schedule 3.22, No brokers,
finders or other similar advisory fees or commissions will be payable by the Company or any Subsidiary or by any of their respective
agents with respect to the issuance of the Note or any of the other transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.23 </B></FONT><U>OFAC</U>.
None of the Company nor any of the Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate
or person acting on behalf of the Company and/or any Subsidiary has been or is currently subject to any United States sanctions administered
by the Office of Foreign Assets Control of the United States Department of the Treasury (&ldquo;<B>OFAC</B>&rdquo;); and the Company will
not directly or indirectly use any proceeds received from the Investor, or lend, contribute or otherwise make available such proceeds
to its Subsidiaries or to any affiliated entity, joint venture partner or other person or entity, to finance any investments in, or make
any payments to, any country or person currently subject to any of the sanctions of the United States administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.24 </B></FONT><U>No
Foreign Corrupt Practices</U>. None of the Company or any of the Subsidiaries has, directly or indirectly: (a) made or authorized any
contribution, payment or gift of funds or property to any official, employee or agent of any governmental authority of any jurisdiction
except as otherwise permitted under applicable Law; or (b) made any contribution to any candidate for public office, in either case, where
either the payment or the purpose of such contribution, payment or gift was, is, or would be prohibited under the Foreign Corrupt Practices
Act or the rules and regulations promulgated thereunder or under any other legislation of any relevant jurisdiction covering a similar
subject matter applicable to the Company or its Subsidiaries and their respective operations and the Company has instituted and maintained
policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance with such legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.25 </B></FONT><U>Anti-Money
Laundering</U>. The operations of each of the Company and the Subsidiaries are and have been conducted at all times in compliance with
all applicable anti-money laundering laws, regulations, rules and guidelines in its jurisdiction of incorporation and in each other jurisdiction
in which such entity, as the case may be, conducts business (collectively, the &ldquo;<B>Money Laundering Laws</B>&rdquo;) and no action,
suit or proceeding by or before any court or governmental authority involving the Company or its Subsidiaries with respect to any of the
Money Laundering Laws is, to the knowledge of the Company, pending, threatened or contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.26 </B></FONT><U>Disclosure</U>.
The Company confirms that neither it, nor to its knowledge, any other Person acting on its behalf has provided the Investor or its agents
or counsel with any information that the Company believes constitutes material, non-public information. The Company understands and confirms
that the Investor will rely on the foregoing representations and covenants in effecting transactions in securities of the Company. All
disclosures provided to the Investor regarding the Company, its business and the transactions contemplated hereby, furnished by or on
behalf of the Company (including the Company&rsquo;s representations and warranties set forth in this Agreement) are true and correct
in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements made therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>4.
</B></FONT><B><U>REPRESENTATIONS AND WARRANTIES OF THE INVESTOR</U></B>. The Investor represents and warrants to the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.1
</B></FONT><U>Organization and Qualification</U>. The Investor is a limited partnership, duly formed and validly existing in good standing
under the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.2
</B></FONT><U>Authorization; Enforcement; Compliance with Other Instruments</U>. The Investor has the requisite power and authority to
enter into this Agreement, to purchase the Note and the Warrant and to perform its obligations under the Transaction Documents. The execution
and delivery of the Transaction Documents to which it is a party have been duly and validly authorized by the Investor&rsquo;s governing
body and no further consent or authorization is required. The Transaction Documents to which it is a party have been duly and validly
executed and delivered by the Investor and constitute valid and binding obligations of the Investor, enforceable against the Investor
in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors&rsquo;
rights and remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.3
</B></FONT><U>No Conflicts</U>. The execution, delivery and performance of the Transaction Documents to which it is a party by the Investor
and the purchase of the Note and the Warrant by the Investor will not (a) conflict with or result in a violation of the Investor&rsquo;s
organizational documents, (b) conflict with, or constitute a material default (or an event which, with notice or lapse of time or both,
would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any
material agreement, contract, indenture mortgage, indebtedness or instrument to which the Investor is a party, or (c) violate in any
material respect any Law applicable to the Investor or by which any of the Investor&rsquo;s properties or assets are bound or affected.
No approval or authorization will be required from any governmental authority or agency, regulatory or self-regulatory agency or other
third party in connection with the purchase of the Note and the Warrant and the other transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.4
</B></FONT><U>Investment Intent; Accredited Investor</U>. The Investor is purchasing the Note and the Warrant for its own account, for
investment purposes, and not with a view towards distribution. The Investor is an &ldquo;accredited investor&rdquo; as such term is defined
in Rule 501(a) of Regulation D of the 1933 Act. The Investor has, by reason of its business and financial experience, such knowledge,
sophistication and experience in financial and business matters and in making investment decisions of this type that it is capable of
(a) evaluating the merits and risks of an investment in the Note, the Warrant and the Investor Shares and making an informed investment
decision, (b) protecting its own interests and (c) bearing the economic risk of such investment for an indefinite period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>4.5
</B></FONT><U>No Other Representations.</U>&#9;Except for the representations and warranties set forth in this Agreement and in other
Transaction Documents, the Investor makes no other representations or warranties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>5.
</B></FONT><B>OTHER AGREEMENTS OF THE PARTIES</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.1 </B></FONT><U>Legends,
etc</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) Securities
may only be disposed of pursuant to an effective registration statement under the 1933 Act, to the Company or pursuant to an available
exemption from or in a transaction not subject to the registration requirements of the 1933 Act, and in compliance with any applicable
state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) Certificates
evidencing the Securities will contain the following legend, so long as is required by this <U>Section 5.1(b)</U> or <U>Section 5.1(c)</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">[NEITHER THESE SECURITIES
NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED] [THESE SECURITIES HAVE NOT BEEN REGISTERED] WITH THE
SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. [THESE SECURITIES
AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES] [THESE SECURITIES] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges and
agrees that the Investor may from time to time pledge, and/or grant a security interest in some or all of the Securities, in accordance
with applicable securities laws, pursuant to a bona fide margin agreement in connection with a bona fide margin account and, if required
under the terms of such agreement or account, the Investor may transfer pledged or secured Securities to the pledgees or secured parties.
Such a pledge or transfer would not be subject to approval or consent of the Company and no legal opinion of legal counsel to the pledgee,
secured party or pledgor shall be required in connection with the pledge, but such legal opinion may be required in connection with a
subsequent transfer following default by the Investor transferee of the pledge. No notice shall be required of such pledge. At the Company&rsquo;s
expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably
request in connection with a pledge or transfer of the Securities including the preparation and filing of any required prospectus supplement
under Rule 424(b)(3) of the 1933 Act or other applicable provision of the 1933 Act to appropriately amend the list of selling stockholders
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) Certificates
evidencing the Investor Shares shall not contain any legend (including the legend set forth in <U>Section 5.1(b)</U>): (i) while a Registration
Statement is effective under the 1933 Act, (ii) following any sale of such Investor Shares pursuant to Rule 144, (iii) while such Investor
Shares are eligible for sale without restriction under Rule 144, or (iv) if such legend is not required under applicable requirements
of the 1933 Act (including judicial interpretations and pronouncements issued by the Staff of the SEC). The Company shall cause its counsel
to issue any legal opinion or instruction required by the Company&rsquo;s transfer agent to comply with the requirements set forth in
this Section. At such time as a legend is no longer required for the Investor Shares under this <U>Section 5.1(c)</U>, the Company will,
no later than three (3) Business Days following the delivery by the Investor to the Company or the Company&rsquo;s transfer agent of a
certificate representing Investor Shares containing a restrictive legend (such third Business Day, the &ldquo;<B>Legend Removal Date</B>&rdquo;),
deliver or cause to be delivered to the Investor a certificate representing such Investor Shares that is free from all restrictive and
other legends. In addition to any other remedies available to the Investor, the Company shall pay to the Investor, in cash, as partial
liquidated damages and not as a penalty, for each $1,000 of Investor Shares (based on the VWAP of the Common Stock on the date such Investor
Shares are submitted to the Company or the Company&rsquo;s transfer agent) delivered for removal of the restrictive or other legend, $5
per Trading Day for each Trading Day after the Legend Removal Date until such Investor Shares are delivered without a legend.&nbsp; The
Company may not make any notation on its records or give instructions to any transfer agent of the Company that enlarge the restrictions
on transfer set forth in this Section except as it may reasonably determine are necessary or appropriate to comply or to ensure compliance
with those applicable laws that are enacted or modified after the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.2 </B></FONT><U>Furnishing
of Information</U>. As long as the Investor owns the Securities, the Company covenants to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to
the 1934 Act. As long as the Investor owns the Securities, if the Company is not required to file reports pursuant to such laws, it will
prepare and furnish to the Investor and make publicly available in accordance with Rule 144(c) such information as is required for the
Investor to sell the Investor Shares under Rule 144. The Company further covenants that it will take such further action as any holder
of the Securities may reasonably request, all to the extent required from time to time to enable such Person to sell such Investor Shares
without registration under the 1933 Act within the limitation of the exemptions provided by Rule 144 or other applicable exemptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.3 </B></FONT><U>Integration</U>.
The Company shall not, and shall use its best efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit
offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933 Act) that will be integrated with
the offer or sale of the Securities in a manner that would require the registration under the 1933 Act of the sale of the Securities to
the Investor, or that will be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading
Market that would require, under the rules of the Trading Market, the Shareholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.4 </B></FONT><U>Notification
of Certain Events</U>. The Company shall give prompt written notice to the Investor of (a)&nbsp;the occurrence or non-occurrence of any
Event, the occurrence or non-occurrence of which would render any representation or warranty of the Company contained in this Agreement
or any other Transaction Document, if made on or immediately following the date of such Event, untrue or inaccurate in any material respect,
(b)&nbsp;the occurrence of any Event that, individually or in combination with any other Events, has had or could reasonably be expected
to have a Material Adverse Effect, (c)&nbsp;any failure of the Company to comply with or satisfy any covenant or agreement to be complied
with or satisfied by it hereunder or any Event that would otherwise result in the nonfulfillment of any of the conditions to the Investor&rsquo;s
obligations hereunder, (d)&nbsp;any written notice or other written communication from any Person alleging that the consent of such Person
is or may be required in connection with the consummation of the transactions contemplated by this Agreement or any other Transaction
Document, or (e)&nbsp;any Proceeding pending or, to the Company&rsquo;s knowledge, threatened against a party relating to the transactions
contemplated by this Agreement or any other Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>5.5
</B></FONT><U>Available Stock</U>. The Company shall at all times keep authorized and reserved and available for issuance, free of preemptive
rights, such number of shares of Common Stock as are issuable upon repayment or conversion in full of the Note and exercise in full of
the Warrant at any time. If the Company determines at any time that it does not have a sufficient number of authorized Common Stock to
reserve and keep available for issuance as described in this <U>Section 5.5</U>, the Company shall use all commercially reasonable efforts
to increase the number of authorized Common Stock by seeking Shareholder Approval for the authorization of such additional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>5.6
</B></FONT><U>Use of Proceeds</U>. The Company will use the proceeds from the sale of the Note and the Warrant for general working capital
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.7 </B></FONT><U>Repayment
of Indebtedness</U>. The Company shall not make any voluntary cash prepayments on any Indebtedness at any time while any amounts are owing
under the Note other than cash payments the Company is required to make pursuant to the express terms thereof existing on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.8 </B></FONT><U>Intercreditor
Agreement</U>. In the event that the Company or any Subsidiary incurs debt or issues convertible debt securities to a seller as partial
consideration paid to such seller in connection with an Acquisition, unless otherwise waived in writing by the Investor, as a condition
to consummation of such Acquisition, the holder of such debt or convertible debt securities shall enter into an intercreditor agreement
with the Company and the Investor on terms reasonably satisfactory to the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.9 </B></FONT><U>Prohibited
Transactions</U>. The Company hereby covenants and agrees not to enter into any Prohibited Transactions without the Investor&rsquo;s prior
written consent, until the later of (a) thirty (30) days after such time as the Note have been repaid in full, as applicable, and/or have
been converted into Conversion Shares and (b) the date on which the Investor ceases to hold any shares of Common Stock or have the right
to acquire any shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.10 </B></FONT><U>Securities
Laws Disclosure; Publicity</U>. The Company shall, by 9:00 a.m. (New York City time) on the Trading Day immediately following the date
hereof, issue a press release disclosing the material terms of the transactions contemplated hereby (the <B>&ldquo;Press Release&rdquo;</B>),
and shall, within four (4) business days following the date hereof, file a Report on Form 8-K (the <B>&ldquo;Form 8-K&rdquo;</B>) disclosing
the material terms of the transactions contemplated hereby and including this Agreement as an exhibit thereto; provided, that the Company
may not issue the Press Release without the Investor&rsquo;s prior written consent, which shall not be unreasonably withheld. The Company
shall provide a copy of the draft Form 8-K to the Investor for review prior to release and the Company shall incorporate the Investor&rsquo;s
reasonable comments. The Company shall not issue any press release nor otherwise make any such public statement regarding the Investor
or the Transaction Documents without the prior written consent of the Investor, except if such disclosure is made in a manner consistent
with the Press Release or Form 8-K, or is required by law, in which case the Company shall (a) ensure that such disclosure is restricted
and limited in content and scope to the maximum extent permitted by Law to meet the relevant disclosure requirement and (b) provide a
copy of the proposed disclosure to the Investor for review prior to release and the Company shall incorporate the Investor&rsquo;s reasonable
comments. Following the execution of this Agreement, the Investor and its Affiliates and/or advisors may place announcements on their
respective corporate websites and in financial and other newspapers and publications (including, without limitation, customary &ldquo;tombstone&rdquo;
advertisements) describing the Investor&rsquo;s relationship with the Company under this Agreement in a manner consistent with the Press
Release or Form 8-K and including the name and corporate logo of the Company. Notwithstanding anything herein to the contrary, to comply
with United States Treasury Regulations Section 1.6011-4(b)(3)(i), each of the Company and the Investor, and each employee, representative
or other agent of the Company or the Investor, may disclose to any and all persons, without limitation of any kind, the U.S. federal and
state income tax treatment, and the U.S. federal and state income tax structure, of the transactions contemplated hereby and all materials
of any kind (including opinions or other tax analyses) that are provided to such party relating to such tax treatment and tax structure
insofar as such treatment and/or structure relates to a U.S. federal or state income tax strategy provided to such recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.11 </B></FONT><U>Indemnification
of the Investor</U>. Subject to the provisions of this Section 5.11, the Company will indemnify and hold the Investor and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls the Investor (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners
or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such
title or any other title) of such controlling persons (each, a &ldquo;<B>Investor Party</B>&rdquo;) harmless from any and all losses,
liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court
costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Investor Party may suffer or incur as a result of
or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents, (b) any action instituted against the Investor Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Investor Party, with respect to any of the transactions
contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Investor Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Investor Party may have with any such
stockholder or any violations by such Investor Party of state or federal securities laws or any conduct by such Investor Party which is
finally judicially determined to constitute fraud, gross negligence or willful misconduct), (c) any misrepresentation made by the Company
in any Transaction Document or in any SEC Document, (d) any omission to state any material fact necessary in order to make the statements
made in any SEC Document, in light of the circumstances under which they were made, not misleading, or (e) any Proceeding before or by
any court, public board, government agency, self-regulatory organization or body based upon, or resulting from the execution, delivery,
performance or enforcement of any of the Transaction Documents or the consummation of the transactions contemplated thereby, and whether
or not an Investor Party is party thereto by claim, counterclaim, crossclaim, as a defendant or otherwise, or if such Proceeding is based
upon, or results from, any of the items set forth in clauses (a) through (e) above. If any action shall be brought against any Investor
Party in respect of which indemnity may be sought pursuant to this Agreement, such Investor Party shall promptly notify the Company in
writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to
the Investor Party. Any Investor Party shall have the right to employ separate counsel in any such action and participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of such Investor Party except to the extent that (i) the employment
thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume
such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any
material issue between the position of the Company and the position of such Investor Party, in which case the Company shall be responsible
for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Investor Party under
this Agreement (y) for any settlement by an Investor Party effected without the Company&rsquo;s prior written consent, which shall not
be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable
to any Investor Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by such Investor Party in
this Agreement or in the other Transaction Documents. The indemnification required by this <U>Section 5.11</U> shall be made by periodic
payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The
indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Investor Party against the Company
or others and any liabilities the Company may be subject to pursuant to law. The provisions of this <U>Section 5.11</U> shall survive
the termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.12 </B></FONT><U>Non-Public
Information</U>. The Company covenants and agrees that neither it nor any other Person acting on its behalf will provide the Investor
or its agents or counsel with any information that the Company believes constitutes material, non-public information. To the extent the
Company provides the Investor with material, non-public information, the Company shall publicly disclose such information within forty
eight (48) hours of providing the information to the Investor; provided, however, in the event that such material non-public information
is provided to Investor pursuant to <U>Section 10</U>, the Company shall publicly disclose such information within five (5) Business Days
of providing the information to the Investor. The Company understands and confirms that the Investor shall be relying on the foregoing
representation in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.13 </B></FONT><U>Shareholder
Approval</U>. If required by the rules and regulations of the Trading Market or to otherwise fulfill any of its obligations under the
Transaction Documents, the Company shall hold a special meeting of shareholders (which may also be at the annual meeting of shareholders)
on or before the 60th calendar day following the date hereof for the purpose of obtaining the Shareholder Approval; provided, however,
such sixty (60) calendar days shall be increased to ninety (90) calendar days in the event the Company receives comments to its proxy
statement from the SEC, with the recommendation of the Board of Directors that such proposal be approved, and the Company shall solicit
proxies from its shareholders in connection therewith in the same manner as all other management proposals in such proxy statement and
all management-appointed proxyholders shall vote their proxies in favor of such proposal. If the Company does not obtain Shareholder Approval
at the first meeting, the Company shall call a meeting every four months thereafter to seek Shareholder Approval until the date the Shareholder
Approval is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.14 </B></FONT><U>Listing
of Securities</U>. The Company shall: (a) in the time and manner required by each Trading Market on which the Common Stock is listed,
prepare and file with such Trading Market a Listing of Additional Shares form covering the Investor Shares, (b)&nbsp;take all steps necessary
to cause such shares to be approved for listing on each Trading Market on which the Common Stock is listed as soon as possible thereafter,
(c) provide to the Investor evidence of such Trading Market&rsquo;s completion of review of the Listing of Additional Shares form, and
(d) maintain the listing of such shares on each such Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.15 </B></FONT><U>Antitrust
Notification</U>. If the Investor determines, in its sole judgment and upon the advice of counsel, that the issuance of the Note, the
Warrant or the Investor Shares pursuant to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended (the &ldquo;<B>HSR Act</B>&rdquo;), the Company shall file as soon as practicable after the date on which the
Company receives notice from the Investor of the applicability of the HSR Act and a request to so file with the United States Federal
Trade Commission and the United States Department of Justice the notification and report form required to be filed by it pursuant to the
HSR Act in connection with such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.16 </B></FONT><U>Modification
of Prior Transaction Documents</U>. Reference is made hereunder to that certain stock purchase agreement dated as February 23, 2023 by
and between the Investor and the Company and that certain stock purchase warrant (the &ldquo;First Warrant&rdquo;) and convertible promissory
note (the &ldquo;First Note&rdquo;), each issued by the Company in favor of the Investor on February 23, 2023. Concurrently herewith,
the &ldquo;Exercise Price&rdquo; set forth in the First Warrant shall automatically be amended to $2.00 without any further action of
the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.17 </B></FONT><U>Share
Transfer Agent</U>. The Company has informed the Investor of the name of its share transfer agent and represents and warrants that the
transfer agent participates in the Depository Trust Company Fast Automated Securities Transfer program. The Company shall not change its
share transfer agent without the prior written consent of the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.18 </B></FONT><U>Tax
Treatment</U>. The Investor and the Company agree that for U.S. federal income tax purposes, and applicable state, local and non-U.S.
income tax purposes, the Note is not intended to be, and shall not be, treated as indebtedness. Neither the Investor nor the Company shall
take any contrary position on any tax return, or in any audit, claim, investigation, inquiry or proceeding in respect of taxes, unless
otherwise required pursuant to a final determination within the meaning of Section 1313 of the Internal Revenue Code of 1986, as amended,
or any analogous provision of applicable state, local or non-U.S. law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.19 </B></FONT><U>Set-Off</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) The
Investor may set off any of its obligations to the Company (whether or not due for payment), against any of the Company&rsquo;s obligations
to the Investor (whether or not due for payment) under this Agreement and/or any other Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) The
Investor may do anything necessary to effect any set-off undertaken in accordance with this <U>Section 5.16</U> (including varying the
date for payment of any amount payable by the Investor to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>6. </B></FONT><B>CLOSING
CONDITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.1 </B></FONT><U>Conditions
Precedent to the Obligations of the Investor</U>. The obligations of the Investor to fund the Note and acquire the Warrant are subject
to the satisfaction or waiver by the Investor, at or before the Closing of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) <U>Required
Documentation</U>. The Company must have delivered to the Investor (i) a duly executed certificate of an officer of the Company and each
Subsidiary appending thereto (A) copies of duly executed resolutions or consents, of the directors, members or manager, as applicable,
approving and consenting to such party&rsquo;s execution, performance of its obligations under the Transaction Documents and the transaction
contemplated thereby, (B) a certificate of good standing or equivalent document dated no more than five days prior to the date hereof,
in respect of such party, (C) true and correct copies of the organizational documents of such party, and (D) incumbency signatures of
such part, and (ii) copies of each Transaction Document, duly executed by the Company, the Subsidiaries or the Transfer Agent, as applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) <U>Consents
and Permits</U>. The Company must have obtained and delivered to the Investor copies of all necessary permits, approvals, and registrations
necessary to effect this Agreement, the Transaction Documents and any of the transactions contemplated hereby or thereby, including pursuant
to <U>Section 3.14</U> of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) <U>Trading
Market Approval</U>. The Company shall have either (i) obtained and delivered to the Investor copies of all necessary Trading Market approvals
for the issuance of the Note, the Warrant, and, upon the conversion of the Note, the Conversion Shares, and upon exercise of the Warrant,
the Warrant Shares, or (ii) submitted a Listing of Additional Shares Notification Form with the Trading Market relating to the issuance
of the Note, the Warrant, and, upon conversion of the Note, the Conversion Shares, and upon exercise of the Warrant, the applicable Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) <U>No
Event(s) of Default</U>. The Investor must be of the reasonable opinion that no Event of Default has occurred and no Event of Default
would result from the execution of this Agreement or any of the Transaction Documents or the transactions contemplated hereby or thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e) <U>Representations
and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct in all material respects
as of the date when made and as of the Closing Date as though made on and as of such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f) <U>Performance</U>.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required
by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g) <U>No
Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h) <U>No
Suspensions of Trading in Common Stock; Listing</U>. Trading in the Common Stock shall not have been suspended by the SEC or any Trading
Market (except for any suspensions of trading of not more than one day on which the Trading Market is open solely to permit dissemination
of material information regarding the Company) at any time since the date of execution of this Agreement, and the Common Stock shall have
been at all times since such date listed for trading on a Trading Market;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) <U>Limitation
on Beneficial Ownership</U>. The issuance of the Note and the Warrant shall not cause the Investor Group to become, directly or indirectly,
a &ldquo;beneficial owner&rdquo; (within the meaning of Section 13(d) of the 1934 Act and the rules and regulations promulgated thereunder)
of a number of Equity Interests of a class that is registered under the 1934 Act which exceeds the Maximum Percentage of the Equity Interests
of such class that are outstanding at such time; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j) <U>Funds
Flow Request</U>. The Company shall have delivered to the Investor a flow of funds request, substantially in the form set out in <B><U>Exhibit
E</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.2 </B></FONT><U>Conditions
Precedent to the Obligations of the Company</U>. The obligations of the Company to issue the Note and the Warrant are subject to the satisfaction
or waiver by the Company, at or before the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) <U>Representations
and Warranties</U>. The representations and warranties of the Investor contained herein shall be true and correct in all material respects
as of the date when made and as of the Closing Date as though made on and as of such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) <U>Performance</U>.
The Investor shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required
by the Transaction Documents to be performed, satisfied or complied with by the Investor at or prior to the Closing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) <U>No
Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>7. </B></FONT><B><U>EVENTS
OF DEFAULT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.1 </B></FONT><U>Events
of Default</U>. The occurrence of any of the following events shall be an &ldquo;<B>Event of Default</B>&rdquo; under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) an
Event of Default (as defined in the Note);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) any
of the representations or warranties made by the Company or any of its agents, officers, directors, employees or representatives in any
Transaction Document or public filing being inaccurate, false or misleading in any material respect, as of the date as of which it is
made or deemed to be made, including as of the Closing Date, or any certificate or financial or other written statements furnished by
or on behalf of the Company to the Investor or any of its representatives, is inaccurate, false or misleading, in any material respect,
as of the date as of which it is made or deemed to be made, including as of the Closing Date; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) a
failure by the Company to comply with any of its covenants or agreements set forth in this Agreement, including those set forth in <U>Section
9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.2 </B></FONT><U>Investor
Right to Investigate an Event of Default</U>. If in the Investor&rsquo;s reasonable opinion, an Event of Default has occurred, or is or
may be continuing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) the
Investor may notify the Company that is wishes to investigate such purported Event of Default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) the
Company shall cooperate with the Investor in such investigation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) the
Company shall comply with all reasonable requests made by the Investor to the Company in connection with any investigation by the Investor
and shall (i) provide all information requested by the Investor in relation to the Event of Default to the Investor; provided that the
Investor agrees that any materially price sensitive information and/or non-public information will be subject to confidentiality, and
(ii) provide all such requested information within three (3) Business Days of such request; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) the
Company shall pay all reasonable costs incurred by the Investor in connection with any such investigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.3 </B></FONT><U>Remedies
Upon an Event of Default</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) If
an Event of Default occurs pursuant to <U>Section 7.1(a)</U>, the Investor shall have such remedies as are set forth in the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) If
an Event of Default occurs pursuant to <U>Section 7.1(b)</U> or <U>Section&nbsp;7.1(c)</U> and is not remedied within (i) two (2) Business
Days for an Event of Default occurring by the Company&rsquo;s failure to comply with <U>Section 7.1(c)</U>, or (ii) five (5) Business
Days for an Event of Default occurring pursuant to <U>Section 7.1(b)</U>, the Investor may declare, by notice to the Company, effective
immediately, all outstanding obligations by the Company under the Transaction Documents to be immediately due and payable in immediately
available funds and the Investor shall have no obligation to consummate the Closing or to accept the conversion of the Note into Conversion
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>8. </B></FONT><B><U>TERMINATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.1 </B></FONT><U>Events
of Termination</U>. Prior to the occurrence of the Closing, this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) may
be terminated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i) by
the Investor on the occurrence or existence of a Securities Termination Event or a Change of Control; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii) by
either Party, by written notice to the other Party, effective immediately, if the Closing has not occurred within ten (10) Business Days
of the date specified by this Agreement or such later date as the Company and the Investor agree in writing, provided that the right to
terminate this Agreement under this <U>Section 8.1(a)(iii)</U> is not available to any party that is in material breach of or material
default under this Agreement or whose failure to fulfill any obligation under this Agreement has been the principal cause of, or has resulted
in the failure of the Closing to occur; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iii) by
the Investor, in accordance with <U>Section 7.3(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.2 </B></FONT><U>Effect
of Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) Subject
to <U>Section 8.2(b)</U>, each party&rsquo;s right of termination under <U>Section 8.1</U> is in addition to any other rights it may have
under this Agreement or otherwise, and the exercise of a right of termination will not be an election of remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) If
the Investor terminates this Agreement under <U>Section 8.1(a)(i)</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i) the
Investor may declare, by notice to the Company, all outstanding obligations by the Company under the Transaction Documents to be due and
payable without presentment, demand, protest or any other notice of any kind all of which are expressly waived by the Company, anything
to the contrary contained in this Agreement or in any other Transaction Document notwithstanding; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) Nothing
in this Agreement will be deemed to release the Purchaser from any liability for any breach by such party of the terms and provisions
of this Agreement or to impair the right of any party to compel specific performance by any other Party of its obligations under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>9. </B></FONT><B>REGISTRATION
RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.1 </B></FONT><U>Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) <U>Registration
Statement</U>. Promptly, but in any event no later than sixty (60) days from the date of this Agreement, the Company shall prepare and
file with the SEC a Registration Statement (or amendment tot the Company&rsquo;s existing registration statement) covering the resale
of all of the Investor Shares. The foregoing Registration Statement shall be filed on Form S-1 or any successor forms thereto. The Registration
Statement (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided to
the Investor and its counsel at least five (5) Business Days prior to its filing or other submission and the Company shall incorporate
all reasonable comments provided by the Investor or its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) <U>Expenses</U>.
Except as otherwise expressly provided herein, the Company will pay all fees and expenses incident to the performance of or compliance
with this <U>Section 9</U>, including all fees and expenses associated with effecting the registration of the Investor Shares, including
all filing and printing fees, the Company&rsquo;s counsel and accounting fees and expenses, costs associated with clearing the Investor
Shares for sale under applicable state securities laws, listing fees, fees and expenses of one counsel to the Investor and the Investor&rsquo;s
reasonable expenses in connection with the registration, but excluding discounts, commissions, fees of underwriters, selling brokers,
dealer managers or similar securities industry professionals with respect to the Investor Shares being sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) <U>Effectiveness</U>.
The Company shall use its best efforts to have the Registration Statement declared effective as soon as practicable after filing thereof
but in no event later than the date that is ninety (90) days following the Closing Date; provided, however, that such date will be extended
for an additional 15 days in the event that the Company receives comments to the Registration Statement from the SEC. The Company shall
notify the Investor by e-mail as promptly as practicable, and in any event, within twenty-four (24) hours, after the Registration Statement
is declared effective and shall simultaneously provide the Investor with copies of any related Prospectus to be used in connection with
the sale or other disposition of the securities covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) <U>Piggyback
Registration Rights</U>. If the Company at any time determines to file a registration statement under the 1933 Act to register the offer
and sale, by the Company, of Common Stock (other than (x) on Form S-4 or Form S-8 under the 1933 Act or any successor forms thereto, (y)
an at-the-market offering, or (z) a registration of securities solely relating to an offering and sale to employees or directors of the
Company pursuant to any employee stock plan or other employee benefit plan arrangement), the Company shall, as soon as reasonably practicable,
give written notice to the Investor of its intention to so register the offer and sale of Common Stock and, upon the written request,
given within five (5) Business Days after delivery of any such notice by the Company, of the Investor to include in such registration
the Investor Shares (which request shall specify the number of Investor Shares proposed to be included in such registration), the Company
shall cause all such Investor Shares to be included in such registration statement on the same terms and conditions as the Common Stock
otherwise being sold pursuant to such registered offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.2 </B></FONT><U>Company
Obligations</U>. The Company will use its best efforts to effect the registration of the Investor Shares in accordance with the terms
hereof, and pursuant thereto the Company will, as expeditiously as possible:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) use
its commercially reasonable efforts to cause the Registration Statement to become effective and to remain continuously effective for a
period that will terminate upon the first date on which all Investor Shares are either covered by the Registration Statement or may be
sold without restriction, including volume or manner-of-sale restrictions, pursuant to Rule 144 or have been sold by the Investor (the
&ldquo;<B>Effectiveness Period</B>&rdquo;) and advise the Investor in writing when the Effectiveness Period has expired;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) prepare
and file with the SEC such amendments and post-effective amendments and supplements to the Registration Statement and the Prospectus as
may be necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the provisions of the 1933
Act and the 1934 Act with respect to the distribution of all of the Investor Shares covered thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) provide
copies to and permit counsel designated by the Investor to review all amendments and supplements to the Registration Statement no fewer
than three (3) Business Days prior to its filing with the SEC and not file any document to which such counsel reasonably objects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d) furnish
to the Investor and its legal counsel, without charge, (i) promptly after the same is prepared and publicly distributed, filed with the
SEC, or received by the Company (but not later than two (2) Business Days after the filing date, receipt date or sending date, as the
case may be) one copy of the Registration Statement and any amendment thereto, each preliminary prospectus and Prospectus and each amendment
or supplement thereto, and each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence
from the SEC or the staff of the SEC, in each case relating to the Registration Statement (other than any portion of any thereof which
contains information for which the Company has sought confidential treatment), and (ii) such number of copies of a Prospectus, including
a preliminary prospectus, and all amendments and supplements thereto and such other documents as the Investor may reasonably request in
order to facilitate the disposition of the Investor Shares that are covered by the related Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e) immediately
notify the Investor of any request by the SEC for the amending or supplementing of the Registration Statement or Prospectus or for additional
information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f) use
its commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such
order is issued, obtain the withdrawal of any such order at the earliest possible moment and notify the Company of the issuance of any
such order and the resolution thereof, or its receipt of notice of the initiation or threat of any proceeding for such purpose;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g) prior
to any public offering of Investor Shares, use its commercially reasonable efforts to register or qualify or cooperate with the Investor
and its counsel in connection with the registration or qualification of such Investor Shares for offer and sale under the securities or
blue sky laws of such jurisdictions requested by the Investor and do any and all other commercially reasonable acts or things necessary
or advisable to enable the distribution in such jurisdictions of the Investor covered by the Registration Statement and the Company shall
promptly notify the Investor of any notification with respect to the suspension of the registration or qualification of any of such Investor
Shares for sale under the securities or blue sky laws of such jurisdictions or its receipt of notice of the initiation or threat of any
proceeding for such purpose;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h) immediately
notify the Investor, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon the happening of any event
as a result of which, the Registration Statement or Prospectus includes an untrue statement of a material fact or omits to state any material
fact required to be stated therein or necessary to make the statements therein not misleading (in the case of the Prospectus, in light
of the circumstances in which they were made), and promptly prepare, file with the SEC and furnish to such holder a supplement to or an
amendment of such Registration Statement or Prospectus as may be necessary so that such Registration Statement or Prospectus shall not
include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading (in the case of such Prospectus, in light of the circumstances in which they were made);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) otherwise
use its commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the 1933 Act and the 1934
Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j) hold
in confidence and not make any disclosure of information concerning the Investor provided to the Company unless (i) disclosure of such
information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to complete
the Registration Statement or to avoid or correct a misstatement or omission in the Registration Statement, (iii) the release of such
information is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental body of competent jurisdiction,
or (iv) such information has been made generally available to the public other than by disclosure in violation of this Agreement or any
other agreement, and upon learning that disclosure of such information concerning the Investor is sought in or by a court or governmental
body of competent jurisdiction or through other means, give prompt written notice to the Investor and allow the Investor, at the Investor&rsquo;s
expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(k) take
all other reasonable actions necessary to expedite and facilitate disposition by the Investor of all Investor Shares pursuant to the Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.3 </B></FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a) <U>Indemnification
by the Company</U>. The Company will indemnify and hold harmless the Investor Parties, from and against any Losses to which they may become
subject under the 1933 Act or otherwise, arising out of, relating to or based upon: (i) any untrue statement or alleged untrue statement
of any material fact contained in any Registration Statement, any preliminary Prospectus, final Prospectus or other document, including
any Blue Sky Application (as defined below), or any amendment or supplement thereof or any omission or alleged omission of a material
fact required to be stated therein or, in the case of the Registration Statement, necessary to make the statements therein not misleading
or, in the case of any preliminary Prospectus, final Prospectus or other document, necessary to make the statements therein, in light
of the circumstances in which they were made, not misleading; (ii) any Blue Sky Application or other document executed by the Company
specifically for that purpose or based upon written information furnished by the Company filed in any state or other jurisdiction in order
to qualify any or all of the Investor Shares under the securities laws thereof (any such application, document or information herein called
a &ldquo;<B>Blue Sky Application</B>&rdquo;); (iii) any violation or alleged violation by the Company or its agents of the 1933 Act, the
1934 Act or any similar federal or state law or any rule or regulation promulgated thereunder applicable to the Company or its agents
and relating to any action or inaction required of the Company in connection with the registration or the offer or sale of the Investor
Shares pursuant to any Registration Statement; or (iv) any failure to register or qualify the Investor Shares included in any such Registration
Statement in any state where the Company or its agents has affirmatively undertaken or agreed in writing that the Company will undertake
such registration or qualification on the Investor&rsquo;s behalf and will reimburse the Investor Indemnified Parties for any legal or
other expenses reasonably incurred by them in connection with investigating, preparing or defending any such Losses; <U>provided</U>,
<U>however</U>, that the Company will not be liable in any such case if and to the extent, but only to the extent, that any such Losses
arise out of or are based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with
information furnished by the Investor or any such controlling Person in writing specifically for use in such Registration Statement or
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b) <U>Conduct
of Indemnification Proceedings</U>. Any Person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying
party of any claim, action, suit or proceeding with respect to which it seeks indemnification following such Person&rsquo;s receipt of,
or such Person otherwise become aware of, the commencement of such claim, action, suit or proceeding and (ii) permit such indemnifying
party to assume the defense of such claim, action, suit or proceeding with counsel reasonably satisfactory to the indemnified party; <U>provided</U>,
<U>however</U>, that any Person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate
in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such Person unless (A) the indemnifying
party has agreed to pay such fees or expenses, (B) the indemnifying party shall have failed to assume the defense of such claim and employ
counsel reasonably satisfactory to such Person or (C) in the reasonable judgment of any such Person, based upon written advice of its
counsel, a conflict of interest exists between such Person and the indemnifying party with respect to such claims (in which case, if the
Person notifies the indemnifying party in writing that such Person elects to employ separate counsel at the expense of the indemnifying
party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such Person); and <U>provided</U>,
<U>further</U>, that the failure or delay of any indemnified party to give notice as provided herein shall not relieve the indemnifying
party of its obligations hereunder, except to the extent that such failure or delay to give notice shall materially adversely affect the
indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection
with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for
all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment
or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified
party of a release from all liability in respect of such claim or litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c) <U>Contribution</U>.
If for any reason the indemnification provided for in the preceding paragraph (a) is unavailable to an indemnified party or insufficient
to hold it harmless, other than as expressly specified therein, the indemnifying party shall contribute to the amount paid or payable
by the indemnified party as a result of such Losses in such proportion as is appropriate to reflect the relative fault of the indemnified
party and the indemnifying party, as well as any other relevant equitable considerations. No Person guilty of fraudulent misrepresentation
within the meaning of Section 11(f) of the 1933 Act shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation.
The indemnity and contribution agreements contained in this Section are in addition to any other rights or remedies that any indemnified
party may have under applicable law, by separate agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.4 </B></FONT><U>Effect
of Failure to File and Maintain Effectiveness of any Registration Statement</U>. In addition to any other remedies provided under the
Transaction Documents, if (i) the Registration Statement covering the resale of all of the Investor Shares required to be covered thereby
and required to be filed by the Company pursuant to Section 9.1 is not filed with the SEC on or before the Filing Deadline (a &ldquo;<B>Filing
Failure</B>&rdquo;), (ii) on any day after the effective date of a Registration Statement sales of all of the Registrable Securities required
to be included on such Registration Statement cannot be made pursuant to such Registration Statement (including, without limitation, because
of a failure to keep such Registration Statement effective, a failure to disclose such information as is necessary for sales to be made
pursuant to such Registration Statement, a suspension or delisting of (or a failure to timely list) the shares of Common Stock on a Trading
Market, or a failure to register a sufficient number of shares of Common Stock or by reason of a stop order) or the prospectus contained
therein is not available for use for any reason (a &ldquo;Maintenance Failure&rdquo;), other than the period of time where the Registration
Statement is not effective due to a post-effective amendment filing to the Registration Statement after an Annual Report on Form 10-K
is filed, or (iii) if the Company fails to file with the SEC any required reports under Section 13 or 15(d) of the 1934 Act such that
it is not in compliance with Rule 144(c)(1) (or Rule 144(i)(2), if applicable) (a &ldquo;Current Public Information Failure&rdquo;) as
a result of which the Investor is unable to sell those Investor Shares included in such Registration Statement without restriction under
Rule 144 (including, without limitation, volume restrictions), then, as partial relief for the damages to any holder by reason of any
such delay in, or reduction of, its ability to sell the underlying shares of Common Stock (which remedy shall not be exclusive of any
other remedies available at law or in equity), the Company shall pay to each holder of Investor Shares relating to such Registration Statement
an amount in cash equal to two percent (2.0%) of the Outstanding Principal Amount (I) on the date of such Filing Failure, Maintenance
Failure or Current Public Information Failure, as applicable, and (2) on every thirty (30) day anniversary of (I) a Filing Failure until
such Filing Failure is cured; (II) a Maintenance Failure until such Maintenance Failure is cured; and (III) a Current Public Information
Failure until the earlier of (i) the date such Current Public Information Failure is cured and (ii) such time that such public information
is no longer required pursuant to Rule 144 (in each case, pro-rated for periods totaling less than thirty (30) days). The payments to
which a holder of Investor Shares shall be entitled pursuant to this Section 9.4 are referred to herein as &ldquo;Registration Delay Payments.&rdquo;
Following the initial Registration Delay Payment for any particular event or failure (which shall be paid on the date of such event or
failure, as set forth above), without limiting the foregoing, if an event or failure giving rise to the Registration Delay Payments is
cured prior to any thirty (30) day anniversary of such event or failure, then such Registration Delay Payment shall be made on the third
(3rd) Trading Day after such cure. Notwithstanding the foregoing, (i) no single event or failure with respect to a particular Registration
Statement shall give rise to more than one type of Registration Delay Payment with respect to such Registration Statement, (ii) no Registration
Delay Payments shall be owed to the Investor (with respect to any period during which all of Investor Shares may be sold by the Investor
without restriction under Rule 144 (including, without limitation, volume restrictions) and without the need for current public information
required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable), and (iii) with respect to any Investor Shares excluded from a Registration
Statement by election of the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>10. </B></FONT><B>RIGHTS
TO FUTURE STOCK ISSUANCES.</B> Subject to the terms and conditions of this <U>Section 10</U> and applicable securities laws, if at any
time prior to date that is eighteen (18) months following the Closing, the Company proposes to offer or sell any New Securities (a <B>&ldquo;Subsequent
Financing&rdquo;</B>), the Company shall first offer the Investor the opportunity to purchase up to ten percent (10%) of such New Securities.
The Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate
among itself and&nbsp;its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.1 </B></FONT>The
Company shall give notice (the &ldquo;<B>Offer Notice</B>&rdquo;) to the Investor, stating (a) its bona fide intention to offer such New
Securities, (b) the number of such New Securities to be offered, and (c) the price and terms, if any, upon which it proposes to offer
such New Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.2 </B></FONT>By
notification to the Company within one (1) business day after the date the Offer Notice is given (the <B>&ldquo;Notice Termination Time&rdquo;</B>),
the Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to ten percent
(10%) of such New Securities. If the Company receives no such notice from the Investor as of such Notice Termination Time, the Investor
shall be deemed to have notified the Company that it does not elect to participate in such Subsequent Financing. The closing of any sale
pursuant to this <U>Section 9</U> shall occur within five (5) days of the date that the Offer Notice is given and the date of initial
sale of New Securities pursuant to <U>Section&nbsp;10.3.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.3 </B></FONT>The
Company may, during the five (5) day period following the expiration of the period provided in <U>Section 10.2</U>, offer and sell the
remaining portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree
than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such
period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be
deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this <U>Section
10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.4 </B></FONT>The
right of first offer in this <U>Section 10</U> shall not be applicable to Exempted Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>11. </B></FONT><B><U>GENERAL
PROVISIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.1
</B></FONT><U>Fees and Expenses</U>. At the Closing, the Company shall reimburse the Investor up to $20,000 of due diligence costs and
reasonable fees and disbursements of Lucosky Brookman LLP in connection with the preparation of the Transaction Documents, it being understood
that Lucosky Brookman LLP has not rendered any legal advice to the Company in connection with the transactions contemplated hereby and
that the Company has relied for such matters on the advice of its own counsel. Except as specified above, each party shall pay the fees
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of the Transaction Documents. The Company shall pay all stamp and
other taxes and duties levied in connection with the sale of the Note and the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.2 </B></FONT><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via email
at the email address specified in this Section prior to 5:00 p.m. (New York time) on a Business Day, (b) the next Business Day after the
date of transmission, if such notice or communication is delivered via email at the email address specified in this Section on a day that
is not a Business Day or later than 5:00 p.m. (New York time) on any date and earlier than 11:59 p.m. (New York time) on such date, (c)
the Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (d) upon actual receipt
by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC BioPharma, Inc.,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44370 Old Warm Springs Blvd.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fremont, CA 94538</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Uttam Patil</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Investor:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lind Global Fund II LP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o The Lind Partners LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">444 Madison Avenue, Floor 41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Jeff Easton</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With a copy (which shall not constitute notice) to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lucosky Brookman LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101 Wood Avenue South</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifth Floor</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Woodbridge, NJ</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Seth Brookman</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other address as may be designated in
writing hereafter, in the same manner, by such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.3
</B></FONT><U>Severability</U>. If any provision of this Agreement is held by a court of competent jurisdiction to be excessive in scope
or otherwise invalid or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable to
the maximum extent possible, and the validity and enforceability of the remaining provisions of this Agreement will not in any way be
affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.4
</B></FONT><U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the Laws of the State of Nevada,
without reference to principles of conflict of laws or choice of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.5
</B></FONT><U>Jurisdiction and Venue</U>. Any action, proceeding or claim arising out of, or relating in any way to this Agreement shall
be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District
of New York. The Company and the Investor irrevocably submit to the jurisdiction of such courts, which jurisdiction shall be exclusive,
and hereby waive any objection to such exclusive jurisdiction or that such courts represent an inconvenient forum. The prevailing party
in any such action shall be entitled to recover its reasonable and documented attorneys&rsquo; fees and out-of-pocket expenses relating
to such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.6
</B></FONT><U>WAIVER OF RIGHT TO JURY TRIAL</U>. THE COMPANY AND THE INVESTOR HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED
BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE OTHER
TRANSACTION DOCUMENTS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.7 </B></FONT><U>Survival</U>.
The representations, warranties, agreements and covenants contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.8
</B></FONT><U>Entire Agreement</U>. The Transaction Documents, together with the Exhibits and Schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with
respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.9
</B></FONT><U>Amendments; Waivers</U>. No provision of this Agreement may be waived or amended except in a written instrument signed
by the Company and the Investor. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition
or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise
of any such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.10 </B></FONT><U>Construction</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted
jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement or any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.11
</B></FONT><U>Successors and Assigns</U>. This Agreement shall be binding upon, and inure to the benefit of and be enforceable by, the
Company and the Investor and their respective successors and assigns. The Company may not assign this Agreement or any rights or obligations
hereunder without the prior written consent of the Investor. The Investor may assign any or all of its rights under this Agreement to
any Person to whom the Investor assigns or transfers any Securities, provided such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions hereof that apply to the &ldquo;Investor&rdquo; and such transferee is an accredited
investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.12 </B></FONT><U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.13
</B></FONT><U>Further Assurances</U>. Each party hereto shall do and perform, or cause to be done and performed, all such further acts
and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>11.14
</B></FONT><U>Counterparts</U>. This Agreement may be executed in two identical counterparts, both of which shall be considered one and
the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. Signature
pages delivered by facsimile or e-mail shall have the same force and effect as an original signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.15 </B></FONT><U>Specific
Performance</U>. The Company acknowledges that monetary damages alone would not be adequate compensation to the Investor for a breach
by the Company of this Agreement and the Investor may seek an injunction or an order for specific performance from a court of competent
jurisdiction if (a) the Company fails to comply or threatens not to comply with this Agreement or (b) the Investor has reason to believe
that the Company will not comply with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have executed this Securities Purchase Agreement as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC BIOPHARMA, INC.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Lind GLOBAL FUND II LP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uttam Patil</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff Easton</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Member of Lind Global <BR>
Partners II LLC, General Partner</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page of Securities Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FORM OF NOTE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[See attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FORM OF WARRANT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[See attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>FLOW OF FUNDS REQUEST</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABVC BioPharma, Inc. &ndash; Securities Purchase Agreement &ndash;
Flow of Funds Request</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Securities Purchase Agreement,
dated November 17, 2023 (the &ldquo;Agreement&rdquo;) between ABVC BioPharma, Inc. (the &ldquo;Company&rdquo;) and Lind Global Fund II
LP (the &ldquo;Investor&rdquo;), the Company irrevocably authorizes the Investor to distribute such funds as set out below, in the manner
set out below, at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Capitalized terms used but not otherwise defined in this letter will
have the meaning given to such terms in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours sincerely,</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABVC BIOPHARMA, INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uttam Patil</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">37</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea188623ex10-2_abvcbio.htm
<DESCRIPTION>FORM OF NOTE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THIS
NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN
EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT
BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY. THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE MAY BE PLEDGED IN CONNECTION WITH A BONA
FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABVC
BIOPHARMA, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">Senior<BR>
Convertible Promissory<BR>
Note due May 19, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">Note No. [ &nbsp;&nbsp;]</FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">$1,200,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated: November 17, 2023 (the &ldquo;<U>Issuance Date</U>&rdquo;)</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
value received, ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<U>Maker</U>&rdquo; or the &ldquo;<U>Company</U>"), hereby promises
to pay to the order of Lind Global Fund II LP, a Delaware limited partnership (together with its successors and representatives, the
&ldquo;<U>Holder</U>&rdquo;), in accordance with the terms hereinafter provided, the principal amount of ONE MILLION TWO HUNDRED THOUSAND
DOLLARS ($1,200,000.00) (the &ldquo;<U>Principal Amount</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
payments under or pursuant to this Convertible Promissory Note (this &ldquo;<U>Note</U>&rdquo;) shall be made in United States Dollars
in immediately available funds to the Holder at the address of the Holder set forth in the Purchase Agreement (as hereinafter defined)
or at such other place as the Holder may designate from time to time in writing to the Maker or by wire transfer of funds to the Holder&rsquo;s
account, instructions for which are attached hereto as <U>Exhibit A</U>. The outstanding principal balance of this Note shall be due
and payable on May 19, 2025 (the &ldquo;<U>Maturity Date</U>&rdquo;) or at such earlier time as provided herein; provided, that the Holder,
in its sole discretion, may extend the Maturity Date to any date after the original Maturity Date. In the event that the Maturity Date
shall fall on Saturday or Sunday, such Maturity Date shall be the next succeeding Business Day. All calculations made pursuant to this
Note shall be rounded down to three decimal places.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.1
<U>Purchase Agreement</U>. This Note has been executed and delivered pursuant to the Securities Purchase Agreement, dated as of November
17, 2023 (as the same may be amended from time to time, the &ldquo;<U>Purchase Agreement</U>&rdquo;), by and between the Maker and the
Holder. Capitalized terms used and not otherwise defined herein shall have the meanings set forth for such terms in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.2
<U>Interest</U>. Other than as set forth in <U>Section 2.2</U> herein, this Note shall not bear interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.3
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.4
<U>Prepayment.</U> The Maker may repay all, but not less than all, of the then Outstanding Principal Amount on any date following the
Prepayment Right Date; provided that the Maker shall have given no less than ten (10) day&rsquo;s written notice to the Holder of such
intended prepayment (the &ldquo;<U>Prepayment Notice</U>&rdquo;). If the Maker elects to prepay this Note pursuant to this <U>Section
1.4</U>, the Holder shall have the right (a &ldquo;<U>Prepayment Conversion Notice</U>&rdquo;) within five (5) Business Days of the Holder&rsquo;s
receipt of a Prepayment Notice, to convert up to one third (1/3) of the Principal Amount (the &ldquo;<U>Maximum Amount</U>&rdquo;) at
the Conversion Price (each as defined below), in accordance with the provisions of Article 3, specifying the Principal Amount (up to
the Maximum Amount) that the Holder will convert. Upon delivery of a Prepayment Notice, the Maker irrevocably and unconditionally agrees
to, within five (5) Business Days of receiving a Prepayment Conversion Notice, and if no Prepayment Conversion Notice is received, within
ten (10) Business Days of delivery of a Prepayment Notice: (i) repay the amount of the Outstanding Principal Amount <U>plus</U> the Prepayment
Amount <U>minus </U>the Principal Amount set forth in the Prepayment Conversion Notice and (ii) issue the applicable Conversion Shares
to the Holder in accordance with Article 3, as applicable. The foregoing notwithstanding, the Maker may not deliver a Prepayment Notice
with respect to any Outstanding Principal Amount that is subject to a Conversion Notice delivered by the Holder in accordance with Article
3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.5
<U>Delisting from a Trading Market.</U> If at any time the Common Stock ceases to be listed on a Trading Market, (i) the Holder may deliver
a demand for payment to the Company and, if such a demand is delivered, the Company shall, within ten (10) Business Days following receipt
of the demand for payment from the Holder, pay all of the Outstanding Principal Amount or (ii) the Holder may, at its election, at any
time following the Issuance Date, upon notice to the Company in accordance with <U>Section&nbsp;5.1</U>, convert all or a portion of
the Outstanding Principal Amount and the Conversion Price shall be adjusted to the lower of (A) the then-current Conversion Price and
(A) ninety percent (90%) of the average of the three (3) lowest daily VWAPs during the twenty (20) Trading Days prior to delivery by
the Holder of its notice of conversion pursuant to this <U>Section 1.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.6
<U>Payment on Non-Business Days</U>. Whenever any payment to be made shall be due on a day which is not a Business Day, such payment
may be due on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.7
<U>Transfer</U>. This Note may be transferred or sold, subject to the provisions of <U>Section 5.8</U> of this Note, or pledged, hypothecated
or otherwise granted as security by the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.8
<U>Replacement</U>. Upon receipt of a duly executed and notarized written statement from the Holder with respect to the loss, theft or
destruction of this Note (or any replacement hereof), or, in the case of a mutilation of this Note, upon surrender and cancellation of
such Note, the Maker shall issue a new Note, of like tenor and amount, in lieu of such lost, stolen, destroyed or mutilated Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.9
<U>Use of Proceeds</U>. The Maker shall use the proceeds of this Note as set forth in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.10
<U>Status of Note</U>. The obligations of the Maker under this Note shall be senior to all other existing Indebtedness and equity of
the Company. Upon any Liquidation Event (as hereinafter defined), the Holder will be entitled to receive, before any distribution or
payment is made upon, or set apart with respect to, any Indebtedness of the Maker or any class of capital stock of the Maker, an amount
equal to the Outstanding Principal Amount. For purposes of this Note, &ldquo;<U>Liquidation Event</U>&rdquo; means a liquidation pursuant
to a filing of a petition for bankruptcy under applicable law or any other insolvency or debtor&rsquo;s relief, an assignment for the
benefit of creditors, or a voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Maker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.11
<U>Tax Treatment</U>. The Maker and the Holder agree that for U.S. federal income tax purposes, and applicable state, local and non-U.S.
income tax purposes, this Note is not intended to be, and shall not be, treated as indebtedness. Neither the Maker nor the Holder shall
take any contrary position on any tax return, or in any audit, claim, investigation, inquiry or proceeding in respect of Taxes, unless
otherwise required pursuant to a final determination within the meaning of Section 1313 of the Internal Revenue Code of 1986, as amended
(the &ldquo;<U>Code</U>&rdquo;), or any analogous provision of applicable state, local or non-U.S. law.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1
<U>Events of Default</U>. An &ldquo;<U>Event of Default</U>&rdquo; under this Note shall mean the occurrence of any of the events defined
in the Purchase Agreement, and any of the additional events described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
any default in the payment of (i) the Principal Amount or any accrued and unpaid interest hereunder when due, or any principal or interest
owing under any other Note; or (ii)&nbsp;liquidated damages in respect of this Note or any other Note as and when the same shall become
due and payable (whether on the Maturity Date or by acceleration or otherwise);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
the Maker shall fail to observe or perform any other covenant, condition or agreement contained in this Note or any Transaction Document;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
the Maker&rsquo;s notice to the Holder, including by way of public announcement, at any time, of its inability to comply (including for
any of the reasons described in <U>Section 3.6(a)</U> hereof) or its intention not to comply with proper requests for conversion of this
Note into Common Stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
the Maker shall fail to (i) timely deliver the shares of Common Stock as and when required in <U>Section 3.2</U>; or (ii) make the payment
of any fees and/or liquidated damages under this Note, the Purchase Agreement or the other Transaction Documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)
default shall be made in the performance or observance of any material covenant, condition or agreement contained in the Purchase Agreement
or any other Transaction Document that is not covered by any other provisions of this <U>Section 2.1;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)
at any time the Maker shall fail to have 200% of a sufficient number of shares of Common Stock authorized, reserved and available for
issuance to satisfy the potential conversion in full (disregarding for this purpose any and all limitations of any kind on such conversion)
of this Note or upon exercise of the Warrant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)
any representation or warranty made by the Maker or any of its Subsidiaries herein or in the Purchase Agreement, the Note, the Warrant
or any other Transaction Document shall prove to have been false or incorrect or breached in a material respect on the date as of which
made;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)
unless otherwise approved in writing in advance by the Holder, the Maker shall, or shall announce an intention to pursue or consummate
a Change of Control, or a Change of Control shall be consummated, or the Maker shall negotiate, propose or enter into any agreement,
understanding or arrangement with respect to any Change of Control;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)
the Maker or any of its Subsidiaries shall (A) default in any payment of any amount or amounts of principal of or interest (if any) on
any Indebtedness (other than the Indebtedness hereunder), the aggregate principal amount of which Indebtedness is in excess of $100,000
or (B) default in the observance or performance of any other agreement or condition relating to any such Indebtedness or contained in
any instrument or agreement evidencing, securing or relating thereto, or any other event shall occur or condition exist, the effect of
which default or other event or condition is to cause, or to permit the holder or holders or beneficiary or beneficiaries of such Indebtedness
to cause with the giving of notice if required, such Indebtedness to become due prior to its stated maturity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)
the Maker or any of its Subsidiaries shall: (i) apply for or consent to the appointment of, or the taking of possession by, a receiver,
custodian, trustee or liquidator of itself or of all or a substantial part of its property or assets; (ii) make a general assignment
for the benefit of its creditors; (iii) commence a voluntary case under the United States Bankruptcy Code (as now or hereafter in effect)
or under the comparable laws of any jurisdiction (foreign or domestic); (iv) file a petition seeking to take advantage of any bankruptcy,
insolvency, moratorium, reorganization or other similar law affecting the enforcement of creditors&rsquo; rights generally; (v) acquiesce
in writing to any petition filed against it in an involuntary case under United States Bankruptcy Code (as now or hereafter in effect)
or under the comparable laws of any jurisdiction (foreign or domestic); (vi) issue a notice of bankruptcy or winding down of its operations
or issue a press release regarding same; or (vii)&nbsp;take any action under the laws of any jurisdiction (foreign or domestic) analogous
to any of the foregoing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)
a proceeding or case shall be commenced in respect of the Maker or any of its Subsidiaries, without its application or consent, in any
court of competent jurisdiction, seeking: (i) the liquidation, reorganization, moratorium, dissolution, winding up, or composition or
readjustment of its debts; (ii) the appointment of a trustee, receiver, custodian, liquidator or the like of it or of all or any substantial
part of its assets in connection with the liquidation or dissolution of the Maker or any of its Subsidiaries; or (iii) similar relief
in respect of it under any law providing for the relief of debtors, and such proceeding or case described in clause (i), (ii) or (iii)
shall continue undismissed, or unstayed and in effect, for a period of forty-five (45) days or any order for relief shall be entered
in an involuntary case under United States Bankruptcy Code (as now or hereafter in effect) or under the comparable laws of any jurisdiction
(foreign or domestic) against the Maker or any of its Subsidiaries or action under the laws of any jurisdiction (foreign or domestic)
analogous to any of the foregoing shall be taken with respect to the Maker or any of its Subsidiaries and shall continue undismissed,
or unstayed and in effect for a period of forty-five (45) days;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)
one or more final judgments or orders for the payment of money aggregating in excess of $100,000 (or its equivalent in the relevant currency
of payment) are rendered against one or more of the Company and its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)
the failure of the Maker to instruct the Transfer Agent to remove any legends from shares of Common Stock and issue such unlegended certificates
to the Holder within three (3) Trading Days of the Holder&rsquo;s request so long as the Holder has provided reasonable assurances to
the Maker that such shares of Common Stock can be sold pursuant to Rule 144 or any other applicable exemption;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)
the Maker&rsquo;s Common Stock is no longer publicly traded or ceases to be listed on the Trading Market or, after the six month anniversary
of the Issuance Date, any Investor Shares may not be immediately resold under Rule 144 without restriction on the number of shares to
be sold or manner of sale, unless such Investor Shares have been registered for resale under the 1933 Act and may be sold without restriction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(o)
the Maker proposes to or does consummate a &ldquo;going private&rdquo; transaction as a result of which the Common Stock will no longer
be registered under Sections 12(b) or 12(g) of the 1934 Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(p)
there shall be any SEC or judicial stop trade order or trading suspension stop-order or any restriction in place with the Transfer Agent
restricting the trading of such Common Stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(q)
the Depository Trust Company places any restrictions on transactions in the Common Stock or the Common Stock are no longer tradeable
through the Depository Trust Company Fast Automated Securities Transfer program;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(r)
Intentionally Left Blank; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(s)
the occurrence of a Material Adverse Effect in respect of the Maker, or the Maker and its Subsidiaries taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the avoidance of doubt, any default pursuant to clause (i) above shall not be subject to any cure periods pursuant to the instrument
governing such Indebtedness or this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2
<U>Remedies Upon an Event of Default</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
Upon the occurrence of any Event of Default , the Maker shall be obligated to pay to the Holder the Mandatory Default Amount, which Mandatory
Default Amount shall be earned by the Holder on the date the Event of Default giving rise thereto occurs and shall be due and payable
on the earlier to occur of the Maturity Date, upon conversion, redemption or prepayment of this Note or the date on which all amounts
owing hereunder have been accelerated in accordance with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
Upon the occurrence of any Event of Default, the Maker shall, as promptly as possible but in any event within one (1) Business Day of
such Event of Default, notify the Holder of the occurrence of such Event of Default, describing the event or factual situation giving
rise to the Event of Default and specifying the relevant subsection or subsections of <U>Section 2.1</U> hereof under which such Event
of Default has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
Upon the occurrence and during the continuance of an Event of Default<U>,</U> the Holder may at any time at its option (1) declare the
Mandatory Default Amount due and payable, and thereupon, the same shall be accelerated and so due and payable, without presentment, demand,
protest or notice, all of which are hereby expressly unconditionally and irrevocably waived by the Maker and (2) exercise all other rights
and remedies available to it under the Transaction Documents; <I>provided, however</I>, that (x) upon the occurrence of an Event of Default
described above or an event which with the passage of time may result in an Event of Default, the Holder, in its sole and absolute discretion
(without the obligation to provide notice of such Event of Default or potential Event of Default), may: (a) from time-to-time demand
that all or a portion of the Outstanding Principal Amount be converted into shares of Common Stock at the lower of (i) the then-current
Conversion Price and (ii) eighty-percent (80%) of the average of the three (3) lowest daily VWAPs during the twenty (20) Trading Days
prior to the delivery by the Holder of the applicable notice of conversion or (b) exercise or otherwise enforce any one or more of the
Holder&rsquo;s rights, powers, privileges, remedies and interests under this Note, the Purchase Agreement, the other Transaction Documents
or applicable law and (y) upon the occurrence of an Event of Default described in <U>Section 2.1(k)</U> above, the Mandatory Default
Amount shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby
waived by the Maker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
No course of delay on the part of the Holder shall operate as a waiver thereof or otherwise prejudice the rights of the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)
No remedy conferred hereby shall be exclusive of any other remedy referred to herein or now or hereafter available at law, in equity,
by statute or otherwise.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1
<U>Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
<U>Conversion</U>. At any time following the earlier to occur of (i) the first one hundred twenty days (120) following the date hereof
or (ii) the effective date of the Registration Statement, this Note shall be convertible (in whole or in part), at the option of the
Holder, into such number of fully paid and non-assessable Common Stock as is determined by dividing (x) that portion of the Outstanding
Principal Amount that the Holder elects to convert (the &ldquo;<U>Conversion Amount</U>&rdquo;) by (y) the Conversion Price then in effect
on the date on which the Holder delivers a notice of conversion, in substantially the form attached hereto as <U>Exhibit B</U> (the &ldquo;<U>Conversion
Notice</U>&rdquo;), in accordance with the instructions set forth in <U>Section 5.1</U> to the Maker. The Holder shall deliver this Note
to the Maker at the address designated in the Purchase Agreement at such time that this Note is fully converted. With respect to partial
conversions of this Note, the Maker shall keep written records of the amount of this Note converted as of the date of such conversion
(each, a &ldquo;<U>Conversion Date</U>&rdquo;). Any amounts of the Outstanding Principal Amount converted hereunder shall be credited
to the next scheduled Monthly Payment, or if any amount of the Outstanding Principal Amount converted hereunder exceeds the next scheduled
Monthly Payment, future Monthly Payments shall be credited, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
<U>Conversion Price</U>. The &ldquo;<U>Conversion Price</U>&rdquo; means the lesser of (i) $3.50 (the &ldquo;<U>Fixed Price</U>&rdquo;)
and (ii) 90% of the three lowest VWAPs during the 20 trading days prior to conversion (&ldquo;<U>Variable Price</U>&rdquo;), and shall
be subject to adjustment as provided herein. Notwithstanding the foregoing, provided that no Event of Default shall have occurred, conversions
hereunder shall be at the Fixed Price for the first one hundred eighty days (180) following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
<U>Conversion Limits</U>. With respect to conversions at the Variable Price, such conversions hereunder shall be limited on a monthly
basis, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until
the First Note has been repaid in full: Conversions allowed up to $150,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thereafter:
Conversions allowed up to $200,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the foregoing, (i) the Holder shall have the right to convert up to $350,000 at the Variable Price for two months while this Note is
outstanding and (ii) in the event that the Company&rsquo;s Market Capitalization is below $5,000,000 for ten (10) consecutive days, there
shall be no limitations on conversion of this Note at the Variable Price. For the purposes of clarity, there shall be no conversion limits
at the Fixed Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2
<U>Delivery of Conversion Shares</U>. As soon as practicable after the occurrence of any event requiring the issuance of Common Stock
issuable upon conversion of this Note (&ldquo;<U>Conversion Shares</U>&rdquo;), and in any event within two (2) Business Days thereafter
(such date, the &ldquo;<U>Share Delivery Date</U>&rdquo;), the Maker shall, at its expense, cause to be issued in the name of and delivered
to the Holder, or as the Holder may direct, a certificate or certificates evidencing the number of fully paid and nonassessable Common
Stock to which the Holder shall be entitled, in such denominations as may be requested by the Holder, which certificate or certificates
shall be free of restrictive and trading legends, except for any such legends as may be required under the Securities Act. In lieu of
delivering physical certificates for the shares of Common Stock issuable upon the occurrence of any event requiring the issuance of Conversion
Shares in accordance with this Note, provided the Transfer Agent is participating in the Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;)
Fast Automated Securities Transfer program or a similar program, upon request of the Holder, the Company shall cause the Transfer Agent
to electronically transmit such Conversion Shares so issuable to the Holder (or its designee), by crediting the account of the Holder&rsquo;s
(or such designee&rsquo;s) broker with DTC through its Deposit and Withdrawal At Custodian (&ldquo;<U>DWAC</U>&rdquo;) system (provided
that the same time periods herein as for stock certificates shall apply) as instructed by the Holder (or its designee); provided, that
such issuance shall only be made through DTC&rsquo;s DWAC system if such Conversion Shares will be issued free of restrictive legends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3
<U>Ownership Cap</U>. Notwithstanding anything to the contrary contained herein, the Holder shall not be entitled to receive shares representing
Equity Interests upon conversion of this Note to the extent (but only to the extent) that such exercise or receipt would cause the Holder
Group (as defined below) to become, directly or indirectly, a &ldquo;beneficial owner&rdquo; (within the meaning of Section 13(d) of
the 1934 Act and the rules and regulations promulgated thereunder) of a number of Equity Interests of a class that is registered under
the 1934 Act which exceeds the Maximum Percentage (as defined in the Purchase Agreement) of the Equity Interests of such class that are
outstanding at such time. Any purported delivery of Equity Interests in connection with the conversion of this Note prior to the termination
of this restriction in accordance herewith shall be void and have no effect to the extent (but only to the extent) that such delivery
would result in the Holder Group becoming the beneficial owner of more than the Maximum Percentage of the Equity Interests of a class
that is registered under the 1934 Act that is outstanding at such time. If any delivery of Equity Interests owed to the Holder following
conversion of this Note is not made, in whole or in part, as a result of this limitation, the Company&rsquo;s obligation to make such
delivery shall not be extinguished and the Company shall deliver such Equity Interests as promptly as practicable after the Holder gives
notice to the Company that such delivery would not result in such limitation being triggered or upon termination of the restriction in
accordance with the terms hereof. To the extent limitations contained in this <U>Section 3.3</U> apply, the determination of whether
this Note is convertible and of which portion of this Note is convertible shall be the sole responsibility and in the sole determination
of the Holder, and the submission of a notice of conversion shall be deemed to constitute the Holder&rsquo;s determination that the issuance
of the full number of Conversion Shares requested in the notice of conversion is hereunder, and the Company shall not have any obligation
to verify or confirm the accuracy of such determination. For purposes of this <U>Section 3.3</U>, (i)&nbsp;the term &ldquo;<U>Maximum
Percentage</U>&rdquo; shall mean 4.99%; provided, that if at any time after the date hereof the Holder Group beneficially owns in excess
of 4.99% of any class of Equity Interests in the Company that is registered under the 1934 Act, then the Maximum Percentage shall automatically
increase to 9.99% so long as the Holder Group owns in excess of 4.99% of such class of Equity Interests (and shall, for the avoidance
of doubt, automatically decrease to 4.99% upon the Holder Group ceasing to own in excess of 4.99% of such class of Equity Interests);
and (ii) the term &ldquo;<U>Holder Group</U>&rdquo; shall mean the Holder plus any other Person with which the Holder is considered to
be part of a group under Section 13 of the 1934 Act or with which the Holder otherwise files reports under Sections&nbsp;13 and/or 16
of the 1934 Act. In determining the number of Equity Interests of a particular class outstanding at any point in time, the Holder may
rely on the number of outstanding Equity Interests of such class as reflected in (x) the Company&rsquo;s most recent Annual Report on
Form 20-F filed with the Securities and Exchange Commission, as the case may be, (y) a more recent public announcement by the Company
or (z) a more recent notice by the Company or the Transfer Agent to the Holder setting forth the number of Equity Interests of such class
then outstanding. For any reason at any time, upon written or oral request of the Holder, the Company shall, within one (1) Business
Day of such request, confirm orally and in writing to the Holder the number of Equity Interests of any class then outstanding. The provisions
of this <U>Section 3.3</U> shall be construed, corrected and implemented in a manner so as to effectuate the intended beneficial ownership
limitation herein contained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4
<U>Adjustment of Conversion Price</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
Until the Note has been paid in full or converted in full, the Conversion Price shall be subject to adjustment from time to time as follows
(but shall not be increased, other than pursuant to <U>Section 3.4(a)(i)</U> hereof):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)
<U>Adjustments for Stock Splits and Combinations</U>. If the Maker shall at any time or from time to time after the Closing Date (but
whether before or after the Issuance Date) effect a split or other subdivision of the outstanding Common Stock, the applicable Conversion
Price in effect immediately prior to the stock split shall be proportionately decreased. If the Maker shall at any time or from time
to time after the Closing Date (but whether before or after the Issuance Date), combine the outstanding Common Stock, the applicable
Conversion Price in effect immediately prior to the combination shall be proportionately increased. Any adjustments under this <U>Section
3.4(a)(i)</U> shall be effective at the close of business on the date the stock split or combination occurs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)
<U>Adjustments for Certain Dividends and Distributions</U>. If the Maker shall at any time or from time to time after the Closing Date
(but whether before or after the Issuance Date) make or issue or set a record date for the determination of holders of Common Stock entitled
to receive a dividend or other distribution payable in Common Stock, then, and in each event, the applicable Conversion Price in effect
immediately prior to such event shall be decreased as of the time of such issuance or, in the event such record date shall have been
fixed, as of the close of business on such record date, by multiplying the applicable Conversion Price then in effect by a fraction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of
such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend
or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)
<U>Adjustment for Other Dividends and Distributions</U>. If the Maker shall at any time or from time to time after the Closing Date (but
whether before or after the Issuance Date) make or issue or set a record date for the determination of holders of Common Stock entitled
to receive a dividend or other distribution payable in other than Common Stock, then, and in each event, an appropriate revision to the
applicable Conversion Price shall be made and provision shall be made (by adjustments of the Conversion Price or otherwise) so that the
Holder of this Note shall receive upon conversions thereof, in addition to the number of shares of Common Stock receivable thereon, the
number of securities of the Maker or other issuer (as applicable) or cash or other property that it would have received had this Note
been converted into shares of Common Stock in full (without regard to any conversion limitations herein) on the date of such event and
had thereafter, during the period from the date of such event to and including the Conversion Date, retained such securities (together
with any distributions payable thereon during such period) or assets, giving application to all adjustments called for during such period
under this <U>Section 3.4(a)(iii)</U> with respect to the rights of the holders of this Note; <I>provided, however</I>, that if such
record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor,
the Conversion Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends or distributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)
<U>Adjustments for Reclassification, Exchange or Substitution</U>. If the shares of Common Stock at any time or from time to time after
the Closing Date (but whether before or after the Issuance Date) shall be changed to the same or different number of shares or other
securities of any class or classes of stock or other property, whether by reclassification, exchange, substitution or otherwise (other
than by way of a stock split or combination of shares or stock dividends provided for in <U>Sections 3.4(a)(i), (ii) and (iii)</U> hereof,
or a reorganization, merger, consolidation, or sale of assets provided for in <U>Section 3.4(a)(vii)</U> hereof), then, and in each event,
an appropriate revision to the Conversion Price shall be made and provisions shall be made (by adjustments of the Conversion Price or
otherwise) so that the Holder shall have the right thereafter to convert this Note into the kind and amount of shares of stock or other
securities or other property receivable upon reclassification, exchange, substitution or other change, by holders of the number of shares
of Common Stock into which such Note might have been converted immediately prior to such reclassification, exchange, substitution or
other change, all subject to further adjustment as provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)
<U>Adjustments for Issuance of Additional Shares of Common Stock</U>. In the event the Maker shall at any time or from time to time after
the Closing Date (but whether before or after the Issuance Date) issue or sell any additional Common Stock (&ldquo;<U>Additional Common
Stock</U>&rdquo;), other than (A) as provided in this Note (including the foregoing subsections (i) through (iv) of this <U>Section 3.4(a)</U>),
pursuant to any Equity Plan (including pursuant to Common Stock Equivalents granted or issued under any Equity Plan), (B) pursuant to
Common Stock Equivalents (as defined below) granted or issued prior to the Closing Date, (C) Exempted Securities, or (D) pursuant to
the terms of this Note, in any case, at an effective price per share that is <B><I>less </I></B>than the Conversion Price then in effect
or without consideration, then the Conversion Price upon each such issuance shall be reduced to a price equal to the consideration per
share paid for such Additional Common Stock. For purposes of clarification, the amount of consideration received for such Additional
Common Stock shall not include the value of any additional securities or other rights received in connection with such issuance of Additional
Common Stock (i.e., warrants, rights of first refusal or other similar rights).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vi)
<U>Issuance, Amendment or Adjustment of Common Stock Equivalents</U>. Except for Exempted Securities, if (x) the Maker, at any time after
the Closing Date (but whether before or after the Issuance Date), shall issue any securities convertible into or exercisable or exchangeable
for, directly or indirectly, Common Stock (&ldquo;<U>Convertible Securities</U>&rdquo;), or any rights or warrants or options to purchase
any such Common Stock or Convertible Securities, other than Common Stock Equivalents granted or issued under any Equity Plan (collectively
with the Convertible Securities, the &ldquo;<U>Common Stock Equivalents</U>&rdquo;) and the price per share for which Common Stock may
be issuable pursuant to any such Common Stock Equivalent shall be <B><I>less </I></B>than the applicable Conversion Price then in effect,
or (y) the price per share for which Common Stock may be issuable under any Common Stock Equivalents is amended or adjusted, pursuant
to the terms of such Common Stock Equivalents or otherwise, and such price as so amended or adjusted shall be less than the applicable
Conversion Price in effect at the time of such amendment or adjustment, then, in each such case (x) or (y), the applicable Conversion
Price upon each such issuance or amendment or adjustment shall be adjusted as provided in subsection (vi) of this <U>Section 3.4(a)</U>
as if the maximum number of shares of Common Stock issuable upon conversion, exercise or exchange of such Common Stock Equivalents had
been issued on the date of such issuance or amendment or adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vii)
<U>Consideration for Stock</U>. In case any Common Stock or any Common Stock Equivalents shall be issued or sold:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
in connection with any merger or consolidation in which the Maker is the surviving corporation (other than any consolidation or merger
in which the previously outstanding Common Stock of the Maker shall be changed to or exchanged for the stock or other securities of another
corporation), the amount of consideration therefor shall be deemed to be the fair value, as determined reasonably and in good faith by
the Board of Directors of the Maker and approved by the Holder, of such portion of the assets and business of the nonsurviving corporation
as such Board of Directors may determine to be attributable to such shares of Common Stock, Convertible Securities, rights or warrants
or options, as the case may be; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
in the event of any consolidation or merger of the Maker in which the Maker is not the surviving corporation or in which the previously
outstanding Common Stock of the Maker shall be changed into or exchanged for the stock or other securities of another corporation or
other property, or in the event of any sale of all or substantially all of the assets of the Maker for stock or other securities or other
property of any corporation, the Maker shall be deemed to have issued shares of Common Stock, at a price per share equal to the valuation
of the Maker&rsquo;s Common Stock based on the actual exchange ratio on which the transaction was predicated, as applicable, and the
fair market value on the date of such transaction of all such stock or securities or other property of the other corporation. If any
such calculation results in adjustment of the applicable Conversion Price, or the number of shares of Common Stock issuable upon conversion
of the Note, the determination of the applicable Conversion Price or the number of shares of Common Stock issuable upon conversion of
the Note immediately prior to such merger, consolidation or sale, shall be made after giving effect to such adjustment of the number
of shares of Common Stock issuable upon conversion of the Note. In the event shares of Common Stock are issued with other shares or securities
or other assets of the Maker for consideration which covers both, the consideration computed as provided in this <U>Section 3.4(a)(vii)
</U>shall be allocated among such securities and assets as determined in good faith by the Board of Directors of the Maker, and approved
by the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(viii)
<U>Record Date</U>. In case the Maker shall take record of the holders of its Common Stock for the purpose of entitling them to subscribe
for or purchase shares of Common Stock or Convertible Securities, then the date of the issue or sale of the shares of Common Stock shall
be deemed to be such record date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
<U>No Impairment</U>. The Maker shall not, by amendment of its Articles of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed hereunder by the Maker, but will at all times in good faith assist in
the carrying out of all the provisions of this <U>Section 3.4</U> and in the taking of all such action as may be necessary or appropriate
in order to protect the conversion rights of the Holder against impairment. In the event the Holder shall elect to convert this Note
as provided herein, the Maker cannot refuse conversion based on any claim that the Holder or anyone associated or affiliated with the
Holder has been engaged in any violation of law, violation of an agreement to which the Holder is a party or for any reason whatsoever,
unless, an injunction from a court, or notice, restraining and or adjoining conversion of this Note shall have issued and the Maker posts
a surety bond for the benefit of the Holder in an amount equal to one hundred fifty percent (150%) of the Principal Amount of the Note
the Holder has elected to convert, which bond shall remain in effect until the completion of arbitration/litigation of the dispute and
the proceeds of which shall be payable to the Holder (as liquidated damages) in the event it obtains judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
<U>Certificates as to Adjustments</U>. Upon occurrence of each adjustment or readjustment of the Conversion Price or number of shares
of Common Stock issuable upon conversion of this Note pursuant to this <U>Section 3.4</U>, the Maker at its expense shall promptly compute
such adjustment or readjustment in accordance with the terms hereof and furnish to the Holder a certificate setting forth such adjustment
and readjustment, showing in detail the facts upon which such adjustment or readjustment is based. The Maker shall, upon written request
of the Holder, at any time, furnish or cause to be furnished to the Holder a like certificate setting forth such adjustments and readjustments,
the applicable Conversion Price in effect at the time, and the number of shares of Common Stock and the amount, if any, of other securities
or property which at the time would be received upon the conversion of this Note. Notwithstanding the foregoing, the Maker shall not
be obligated to deliver a certificate unless such certificate would reflect an increase or decrease of at least one percent (1%) of such
adjusted amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
<U>Issue Taxes</U>. The Maker shall pay any and all issue and other taxes, excluding federal, state or local income taxes, that may be
payable in respect of any issue or delivery of shares of Common Stock on conversion of this Note pursuant thereto; <I>provided, however</I>,
that the Maker shall not be obligated to pay any transfer taxes resulting from any transfer requested by the Holder in connection with
any such conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)
<U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of this Note. In lieu of any fractional
shares to which the Holder would otherwise be entitled, the Maker shall pay cash equal such fractional shares multiplied by the Conversion
Price then in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)
<U>Reservation of Shares of Common Stock</U>. The Maker shall at all times while this Note shall be outstanding, reserve and keep available
out of its authorized but unissued Common Stock, 200% of such number of shares of Common Stock as shall from time to time be sufficient
to effect the conversion of this Note (disregarding for this purpose any and all limitations of any kind on such conversion). The Maker
shall, from time to time, use all commercially reasonable efforts to increase the authorized number of shares of Common Stock or take
other effective action if at any time the unissued number of authorized shares shall not be sufficient to satisfy the Maker&rsquo;s obligations
under this <U>Section&nbsp;3.4(f)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)
<U>Regulatory Compliance</U>. If any shares of Common Stock to be reserved for the purpose of conversion of this Note require registration
or listing with or approval of any governmental authority, stock exchange or other regulatory body under any federal or state law or
regulation or otherwise before such shares may be validly issued or delivered upon conversion, the Maker shall, at its sole cost and
expense, in good faith and as expeditiously as possible, secure such registration, listing or approval, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)
<U>Effect of Events Prior to the Issuance Date</U>. If the Issuance Date of this Note is after the Closing Date, then, if the Conversion
Price or any other right of the Holder of this Note would have been adjusted or modified by operation of any provision of this Note had
this Note been issued on the Closing Date, such adjustment or modification shall be deemed to apply to this Note as of the Issuance Date
as if this Note had been issued on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.5
<U>Prepayment Following a Change of Control</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
<U>Mechanics of Prepayment at Option of Holder in Connection with a Change of Control</U>. No sooner than fifteen (15) days prior to
entry into an agreement for a Change of Control nor later than ten (10) days prior to the consummation of a Change of Control, but not
prior to the public announcement of such Change of Control, the Maker shall deliver written notice (&ldquo;<U>Notice of Change of Control</U>&rdquo;)
to the Holder. At any time after receipt of a Notice of Change of Control (or, in the event a Notice of Change of Control is not delivered
at least ten (10) days prior to a Change of Control, at any time within ten (10) days prior to a Change of Control), the Holder may require
the Maker to prepay, effective immediately prior to the consummation of such Change of Control, an amount equal to the Outstanding Principal
Amount <U>plus</U> five percent (5%) of the Outstanding Principal Amount (the &ldquo;<U>COC Repayment Price</U>&rdquo;), by delivering
written notice thereof (&ldquo;<U>Notice of Prepayment at Option of Holder Upon Change of Control</U>&rdquo;) to the Maker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
<U>Payment of COC Repayment Price</U>. Upon the Maker&rsquo;s receipt of a Notice(s) of Prepayment at Option of Holder Upon Change of
Control from the Holder, the Maker shall deliver the COC Repayment Price to the Holder immediately prior to the consummation of the Change
of Control; provided that the Holder&rsquo;s original Note shall have been so delivered to the Maker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.6
<U>Inability to Fully Convert</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
<U>Holder&rsquo;s Option if Maker Cannot Fully Convert</U>. If, upon the Maker&rsquo;s receipt of a Conversion Notice or as otherwise
required under this Note, including with respect to repayment of principal in Common Stock as permitted under this Note, the Maker cannot
issue Common Stock for any reason, including, without limitation, because the Maker (x) does not have a sufficient number of shares of
Common Stock authorized and available or (y) is otherwise prohibited by applicable law or by the rules or regulations of any stock exchange,
interdealer quotation system or other self-regulatory organization with jurisdiction over the Maker or any of its securities from issuing
all of the shares of Common Stock which are to be issued to the Holder pursuant to this Note, then the Maker shall issue as many shares
of Common Stock as it is able to issue and, with respect to the unconverted portion of this Note or with respect to any shares of Common
Stock not timely issued in accordance with this Note, the Holder, solely at Holder&rsquo;s option, can elect to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)
require the Maker to prepay that portion of this Note for which the Maker is unable to issue Common Stock or for which shares of Common
Stock were not timely issued (the &ldquo;<U>Mandatory Prepayment</U>&rdquo;) at a price equal to the number of shares of Common Stock
that the Maker is unable to issue multiplied by the VWAP on the date of the Conversion Notice (the &ldquo;<U>Mandatory Prepayment Price</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)
void its Conversion Notice and retain or have returned, as the case may be, this Note that was to be converted pursuant to the Conversion
Notice (provided that the Holder&rsquo;s voiding its Conversion Notice shall not affect the Maker&rsquo;s obligations to make any payments
which have accrued prior to the date of such notice); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)
defer issuance of the applicable Conversion Shares until such time as the Maker can legally issue such shares; provided, that the Principal
Amount underlying such Conversion Shares shall remain outstanding until the delivery of such Conversion Shares; provided, further, that
if the Holder elects to defer the issuance of the Conversion Shares, it may exercise its rights under either clause (i) or (ii) above
at any time prior to the issuance of the Conversion Shares upon two (2) Business Days&rsquo; notice to the Maker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
<U>Mechanics of Fulfilling Holder&rsquo;s Election</U>. The Maker shall immediately send to the Holder, upon receipt of a Conversion
Notice from the Holder, which cannot be fully satisfied as described in <U>Section 3.6(a)</U> above, a notice of the Maker&rsquo;s inability
to fully satisfy the Conversion Notice (the &ldquo;<U>Inability to Fully Convert Notice</U>&rdquo;). Such Inability to Fully Convert
Notice shall indicate (i) the reason why the Maker is unable to fully satisfy the Holder&rsquo;s Conversion Notice; and (ii) the amount
of this Note which cannot be converted. The Holder shall notify the Maker of its election pursuant to <U>Section 3.6(a)</U> above by
delivering written notice to the Maker (&ldquo;<U>Notice in Response to Inability to Convert</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
<U>Payment of Mandatory Prepayment Price</U>. If the Holder shall elect to have its Note prepaid pursuant to <U>Section 3.6(a)(i)</U>
above, the Maker shall pay the Mandatory Prepayment Price to the Holder within five (5) Business Days of the Maker&rsquo;s receipt of
the Holder&rsquo;s Notice in Response to Inability to Convert; provided that prior to the Maker&rsquo;s receipt of the Holder&rsquo;s
Notice in Response to Inability to Convert the Maker has not delivered a notice to the Holder stating, to the satisfaction of the Holder,
that the event or condition resulting in the Mandatory Prepayment has been cured and all Conversion Shares issuable to the Holder can
and will be delivered to the Holder in accordance with the terms of this Note. If the Maker shall fail to pay the applicable Mandatory
Prepayment Price to the Holder on the date that is one (1) Business Day following the Maker&rsquo;s receipt of the Holder&rsquo;s Notice
in Response to Inability to Convert, in addition to any remedy the Holder may have under this Note and the Purchase Agreement, such unpaid
amount shall bear interest at the rate of two percent (2%) per month (prorated for partial months) until paid in full. Until the full
Mandatory Prepayment Price is paid in full to the Holder, the Holder may (i) void the Mandatory Prepayment with respect to that portion
of the Note for which the full Mandatory Prepayment Price has not been paid and (ii) receive back such Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
<U>No Rights as Stockholder</U>. Nothing contained in this Note shall be construed as conferring upon the Holder, prior to the conversion
of this Note, the right to vote or to receive dividends or to consent or to receive notice as a stockholder in respect of any meeting
of stockholders for the election of directors of the Maker or of any other matter, or any other rights as a stockholder of the Maker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7
<U>Compensation for Buy-In on Failure to Timely Deliver Conversion Shares</U>.&nbsp; In addition to any other rights available to the
Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder Conversion Shares or any other shares pursuant to
a conversion on or before the Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Conversion Shares which the Holder anticipated receiving upon such conversion (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (a) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Conversion Shares that the Company was required to deliver to the Holder in connection with the conversion at issue times (2) the
price at which the sell order giving rise to such purchase obligation was executed, and (b) at the option of the Holder, either reinstate
the portion of the Note and equivalent number of Conversion Shares for which such conversion was not honored (in which case such conversion
shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its conversion and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (a) of the immediately preceding sentence the Company shall
be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder
in respect of the Buy-In and evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon conversion of the Note as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1
<U>Covenants</U>. For so long as any Note is outstanding, without the prior written consent of the Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
<U>Compliance with Transaction Documents</U>. The Maker shall, and shall cause its Subsidiaries to, comply with its obligations under
this Note and the other Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
<U>Payment of Taxes, Etc</U>. The Maker shall, and shall cause each of its Subsidiaries to, promptly pay and discharge, or cause to be
paid and discharged, when due and payable, all lawful taxes, assessments and governmental charges or levies imposed upon the income,
profits, property or business of the Maker and the Subsidiaries, except for such failures to pay that, individually or in the aggregate,
have not had and would not reasonably be expected to have a Material Adverse Effect; provided, however, that any such tax, assessment,
charge or levy need not be paid if the validity thereof shall currently be contested in good faith by appropriate proceedings and if
the Maker or such Subsidiaries shall have set aside on its books reserves with respect thereto in accordance with generally accepted
accounting principles, and provided, further, that the Maker and such Subsidiaries will pay all such taxes, assessments, charges or levies
forthwith upon the commencement of proceedings to foreclose any lien which may have attached as security therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
<U>Corporate Existence</U>. The Maker shall, and shall cause each of its Subsidiaries to, maintain in full force and effect its corporate
existence, rights and franchises (other than the existence, rights and franchises of the Subsidiaries of the Maker that the board of
directors of the Maker determine are no longer necessary or useful to the operation of the Maker&rsquo;s business) and all licenses and
other rights to use property owned or possessed by it and reasonably deemed to be necessary to the conduct of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
<U>Investment Company Act</U>. The Maker shall conduct its businesses in a manner so that it will not become subject to, or required
to be registered under, the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)
<U>Prohibited Transactions</U>. The Company hereby covenants and agrees not to enter into any Prohibited Transactions until thirty (30)
days after such time as this Note has been converted into Conversion Shares or repaid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)
<U>Repayment of This Note</U>. If the Company or any Subsidiary issues any debt, including any subordinated debt or convertible debt
(other than the Note or any other &ldquo;Note&rdquo; as defined in the Purchase Agreement), or any Equity Interests, other than Exempted
Securities, in one or more transactions, unless otherwise waived in writing by and at the discretion of the Holder, the Company will
immediately utilize the proceeds of such issuance to repay this Note, and if the Company issues any Equity Interests other than Exempted
Securities for aggregate proceeds of more than five million dollars ($5,000,000), unless otherwise waived in writing by and at the discretion
of the Holder, the Company will direct unless otherwise waived in writing by and at the discretion of the Investor, the Company will
direct twenty percent (20%) of the proceeds from such issuance to repay this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)
<U>Minimum Cash Balance</U>. The Company hereby covenants and agrees to maintain a minimum cash balance of one million dollars ($1,000,000)
at all times until this Note has been converted into Conversion Shares or repaid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.2
<U>Set-Off</U>. This Note shall be subject to the set-off provisions set forth in the Purchase Agreement.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via email at the email address specified in this Section prior to 5:00 p.m. (New York time) on a Business Day, (b) the next Business
Day after the date of transmission, if such notice or communication is delivered via email at the email address specified in this Section
on a day that is not a Business Day or later than 5:00 p.m. (New York time) on any date and earlier than 11:59 p.m. (New York time) on
such date, (c) the Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (d)
upon actual receipt by the party to whom such notice is required to be given. The addresses for such notices and communications shall
be as set forth in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2
<U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the Laws of the State of Nevada, without reference
to principles of conflict of laws or choice of laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Note and shall not be deemed to limit
or affect any of the provisions hereof. The language used in this Note will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party. This Note shall be construed as if drafted
jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4
<U>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief</U>. The remedies provided in this Note shall be cumulative
and in addition to all other remedies available under this Note, at law or in equity (including, without limitation, a decree of specific
performance and/or other injunctive relief), no remedy contained herein shall be deemed a waiver of compliance with the provisions giving
rise to such remedy and nothing herein shall limit the Holder&rsquo;s right to pursue actual damages for any failure by the Maker to
comply with the terms of this Note. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the
computation thereof) shall be the amounts to be received by the holder thereof and shall not, except as expressly provided herein, be
subject to any other obligation of the Maker (or the performance thereof). The Maker acknowledges that a breach by it of its obligations
hereunder will cause irreparable and material harm to the Holder and that the remedy at law for any such breach would be inadequate.
Therefore, the Maker agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to
all other available rights and remedies, at law or in equity, to equitable relief, including but not limited to an injunction restraining
any such breach or threatened breach, without the necessity of showing economic loss and without any bond or other security being required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5
<U>Enforcement Expenses</U>. The Maker agrees to pay all costs and expenses of enforcement of this Note, including, without limitation,
attorneys&rsquo; fees and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.6
<U>Binding Effect</U>. The obligations of the Maker and the Holder set forth herein shall be binding upon the successors and assigns
of each such party, whether or not such successors or assigns are permitted by the terms herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.7
<U>Amendments; Waivers</U>. No provision of this Note may be waived or amended except in a written instrument signed by the Company and
the Holder. No waiver of any default with respect to any provision, condition or requirement of this Note shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.8
<U>Compliance with Securities Laws</U>. The Holder of this Note acknowledges that this Note is being acquired solely for the Holder&rsquo;s
own account and not as a nominee for any other party, and for investment, and that the Holder shall not offer, sell or otherwise dispose
of this Note in violation of securities laws. This Note and any Note issued in substitution or replacement therefor shall be stamped
or imprinted with a legend in substantially the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;THIS
NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN
EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT
BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.9
<U>Jurisdiction; Venue</U>. Any action, proceeding or claim arising out of, or relating in any way to this Note shall be brought and
enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York.
The Company and the Holder irrevocably submit to the jurisdiction of such courts, which jurisdiction shall be exclusive, and hereby waive
any objection to such exclusive jurisdiction or that such courts represent an inconvenient forum. The prevailing party in any such action
shall be entitled to recover its reasonable and documented attorneys&rsquo; fees and out-of-pocket expenses relating to such action or
proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.10
<U>Parties in Interest</U>. This Note shall be binding upon, inure to the benefit of and be enforceable by the Maker, the Holder and
their respective successors and permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.11
<U>Failure or Indulgence Not Waiver</U>. No failure or delay on the part of the Holder in the exercise of any power, right or privilege
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude
other or further exercise thereof or of any other right, power or privilege.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.12
<U>Maker Waivers</U>. Except as otherwise specifically provided herein, the Maker and all others that may become liable for all or any
part of the obligations evidenced by this Note, hereby waive presentment, demand, notice of nonpayment, protest and all other demands
and notices in connection with the delivery, acceptance, performance and enforcement of this Note, and do hereby consent to any number
of renewals of extensions of the time or payment hereof and agree that any such renewals or extensions may be made without notice to
any such persons and without affecting their liability herein and do further consent to the release of any person liable hereon, all
without affecting the liability of the other persons, firms or Maker liable for the payment of this Note, AND DO HEREBY WAIVE TRIAL BY
JURY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
No delay or omission on the part of the Holder in exercising its rights under this Note, or course of conduct relating hereto, shall
operate as a waiver of such rights or any other right of the Holder, nor shall any waiver by the Holder of any such right or rights on
any one occasion be deemed a waiver of the same right or rights on any future occasion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
THE MAKER ACKNOWLEDGES THAT THE TRANSACTION OF WHICH THIS NOTE IS A PART IS A COMMERCIAL TRANSACTION, AND TO THE EXTENT ALLOWED BY APPLICABLE
LAW, HEREBY WAIVES ITS RIGHT TO NOTICE AND HEARING WITH RESPECT TO ANY PREJUDGMENT REMEDY WHICH THE HOLDER OR ITS SUCCESSORS OR ASSIGNS
MAY DESIRE TO USE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.13
<U>Definitions</U>. Capitalized terms used herein and not defined shall have the meanings set forth in the Purchase Agreement. For the
purposes hereof, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&ldquo;<U>Convertible Securities</U>&rdquo; means any securities convertible into or exercisable or exchangeable for, directly or indirectly,
Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&ldquo;<U>Common Stock Equivalents</U>&rdquo; means any rights or warrants or options to purchase any Common Stock or Convertible Securities,
other than rights or warrants or options to purchase any Common Stock or Convertible Securities granted or issued under any Equity Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
&ldquo;<U>Indebtedness</U>&rdquo; means: (a) all obligations for borrowed money; (b) all obligations evidenced by bonds, debentures,
notes, or other similar instruments and all reimbursement or other obligations in respect of letters of credit, bankers acceptances,
current swap agreements, interest rate hedging agreements, interest rate swaps, or other financial products; (c) all capital lease obligations
that exceed $150,000 in the aggregate in any fiscal year; (d) all obligations or liabilities secured by a lien or encumbrance on any
asset of the Maker, irrespective of whether such obligation or liability is assumed; (e) all obligations for the deferred purchase price
of assets, together with trade debt and other accounts payable that exceed $150,000 in the aggregate in any fiscal year; (f) all synthetic
leases; (g) any obligation guaranteeing or intended to guarantee (whether directly or indirectly guaranteed, endorsed, co-made, discounted
or sold with recourse) any of the foregoing obligations of any other person; (h) trade debt; and (i) endorsements for collection or deposit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
&ldquo;<U>Mandatory Default Amount</U>&rdquo; means an amount equal to one hundred twenty percent (120%) of the Outstanding Principal
Amount of this Note on the date on which the first Event of Default has occurred hereunder and any other amounts owing under this Note
or the other Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)
&ldquo;<U>Market Capitalization</U>&rdquo; means, as of any date of determination, the product of (a) the number of issued and outstanding
shares of Common Stock as of such date (exclusive of any shares of Common Stock issuable upon the exercise of options or warrants or
conversion of any convertible securities), multiplied by (b) the closing price of the Common Stock on the Trading Market on the date
of determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)
&ldquo;<U>Outstanding Principal Amount</U>&rdquo; means, at the time of determination, the Principal Amount outstanding after giving
effect to any adjustments, conversions or prepayments pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)
Intentionally Left Blank</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)
&ldquo;<U>Trading Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)
&ldquo;<U>VWAP</U>&rdquo; means, as of any date, the price determined by the first of the following clauses that applies: (a) if the
Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of one share of Common Stock trading
in the ordinary course of business on the applicable Trading Price for such date (or the nearest preceding date) on such Trading Market
as reported by Bloomberg Financial L.P.; (b) if the Common Stock is not then listed on a Trading Market and if the Common Stock is traded
in the over-the-counter market, as reported by the OTCQX or OTCQB markets, the volume weighted average price of one share of Common Stock
for such date (or the nearest preceding date) on the OTCQX or OTCQB markets, as reported by Bloomberg Financial L.P.; (c) if the Common
Stock is not then listed or quoted on a Trading Market or on the OTCQX or OTCBQ markets and if prices for the Common Stock is then reported
in the &ldquo;Pink Sheets&rdquo; published by the OTC Markets Group (or a similar organization or agency succeeding to its functions
of reporting prices), the most recent bid price of one share of Common Stock so reported, as reported by Bloomberg Financial L.P.; or
(d) in all other cases, the fair market value of one share of Common Stock as determined by an independent appraiser selected in good
faith by the Holder and reasonably acceptable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[Signature
Pages Follow]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">IN
WITNESS WHEREOF, the Maker has caused this Note to be duly executed by its duly authorized officer as of the date first above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABVC
    BIOPHARMA, INC.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uttam Patil</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXHIBIT
A </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WIRE
INSTRUCTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FORM
OF CONVERSION NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(To
be Executed by the Registered Holder in order to Convert the Note)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.8pt 0pt 12.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
undersigned hereby irrevocably elects to convert $ ________________ of the principal amount of the above Note No. ___ into Common Stock
of ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<U>Maker</U>&rdquo;) according to the conditions hereof, as of the date written
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date of Conversion:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion
Price:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of Shares
of Common Stock beneficially owned or deemed beneficially owned by the Holder on the Conversion Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[HOLDER]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ea188623ex10-3_abvcbio.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS WARRANT HAS NOT BEEN REGISTERED WITH THE
SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">The number
of shares of common stock issuable upon exercise of this warrant may be less than the amounts set forth on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant is issued pursuant to that certain
Securities Purchase Agreement dated November 17, 2023 by and between the Company and the Holder (as defined below) (the &ldquo;<U>Purchase
Agreement</U>&rdquo;). Capitalized terms used and not otherwise defined herein shall have the meanings set forth for such terms in the
Purchase Agreement. Receipt of this Warrant by the Holder shall constitute acceptance and agreement to all of the terms contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No. [&nbsp;&nbsp;&nbsp; ] </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ABVC
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COMMON STOCK PURCHASE WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABVC BioPharma, Inc., a Nevada
corporation (together with any corporation which shall succeed to or assume the obligations of ABVC BioPharma, Inc. hereunder, the &ldquo;<U>Company</U>&rdquo;),
hereby certifies that, for value received, Lind Global Fund II LP, a Delaware limited partnership (the &ldquo;<U>Holder</U>&rdquo;), is
entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period (as defined in <U>Section
9</U>) up to [1,000,000] fully paid and non-assessable shares of Common Stock (as defined in <U>Section&nbsp;9</U>), at a purchase price
per share equal to the Exercise Price (as defined in <U>Section 9</U>). The number of shares of Common Stock for which this Common Stock
Purchase Warrant (this &ldquo;<U>Warrant</U>&rdquo;) is exercisable and the Exercise Price are subject to adjustment as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.   <U>DEFINITIONS</U>.
Certain terms are used in this Warrant as specifically defined in <U>Section 9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.   <U>EXERCISE
OF WARRANT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1.   <U>Exercise</U>.
This Warrant may be exercised prior to its expiration pursuant to <U>Section 2.5</U> hereof by the Holder at any time or from time to
time during the Exercise Period, by submitting the form of subscription attached hereto (the &ldquo;<U>Exercise Notice</U>&rdquo;) duly
executed by the Holder, to the Company at its principal office, indicating whether the Holder is electing to purchase a specified number
of shares by paying the Aggregate Exercise Price as provided in <U>Section 2.2</U> or is electing to exercise this Warrant as to a specified
number of shares pursuant to the net exercise provisions of <U>Section 2.3</U>. On or before the first Trading Day following the date
on which the Company has received the Exercise Notice, the Company shall transmit by electronic mail an acknowledgement of confirmation
of receipt of the Exercise Notice. Subject to <U>Section 2.4</U>, this Warrant shall be deemed exercised for all purposes as of the close
of business on the day on which the Holder has delivered the Exercise Notice to the Company. The Aggregate Exercise Price, if any, shall
be paid by wire transfer to the Company within five (5) Business Days of the date of exercise and prior to the time the Company issues
the certificates evidencing the shares issuable upon such exercise. In the event this Warrant is not exercised in full, the Company may,
at its expense, require the Holder, after such partial exercise, to promptly return this Warrant to the Company and the Company will forthwith
issue and deliver to or upon the order of the Holder a new Warrant or Warrants of like tenor, in the name of the Holder or as the Holder
(upon payment by the Holder of any applicable transfer taxes) may request, calling in the aggregate on the face or faces thereof for the
number of shares of Common Stock equal (without giving effect to any adjustment therein) to the number of such shares called for on the
face of this Warrant minus the number of such shares (without giving effect to any adjustment therein) for which this Warrant shall have
been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.   <U>Payment
of Exercise Price by Wire Transfer</U>. If the Holder elects to purchase a specified number of shares by paying the Aggregate Exercise
Price, the Holder shall pay such amount by wire transfer of immediately available funds to the account designated by the Company in its
acknowledgement of receipt of such Exercise Notice pursuant to <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3.   (a)
<U>Net Exercise</U>. If a registration statement covering the shares of Common Stock that are the subject of the Notice of Exercise (the
&ldquo;<U>Unavailable Warrant Shares</U>&rdquo;) is not available for the resale of such Unavailable Warrant Shares to the public or upon
exercise of this Warrant in connection with a Fundamental Transaction, the Holder may elect to exercise this Warrant by receiving shares
of Common Stock equal to the number of shares determined pursuant to the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">X = <U>Y (A - B)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 6%">where,</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>X =</TD>
    <TD>the number of shares of Common Stock to be issued to Holder;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Y =</TD>
    <TD>the number of shares of Common Stock as to which this Warrant is to be exercised (as indicated on the Exercise Notice);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>A =</TD>
    <TD>VWAP for the Trading Day immediately preceding the date of exercise; and </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>B =</TD>
    <TD>the Exercise Price.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) <U>Intentionally Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) <U>Prohibited Transactions</U>.
For the avoidance of doubt, in accordance with Section 5.9 of the Purchase Agreement, the Company agrees that will not to enter into any
Prohibited Transactions without the Holder&rsquo;s prior written consent while this Warrant remains outstanding and thereafter as provided
in such Section 5.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4.   <U>Antitrust
Notification</U>. If the Holder determines, in its sole judgment upon the advice of counsel, that the issuance of any Warrant Shares pursuant
to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &ldquo;<U>HSR
Act</U>&rdquo;), the Company shall file as soon as practicable after the date on which the Company receives notice from the Holder of
the applicability of the HSR Act and a request to so file with the United States Federal Trade Commission and the United States Department
of Justice the notification and report form required to be filed by it pursuant to the HSR Act in connection with such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5.   <U>Termination</U>.
This Warrant shall terminate upon the earlier to occur of (i) exercise in full or (ii) the expiration of the Exercise Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.   <U>REGISTRATION
RIGHTS</U>. The Holder of this Warrant has certain rights to require the Company to register its resale of the Warrant Shares under the
Securities Act and any blue sky or securities laws of any jurisdictions within the United States at the time and in the manner specified
in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.   <U>DELIVERY
OF STOCK CERTIFICATES ON EXERCISE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1.   <U>Delivery
of Exercise Shares</U>. As soon as practicable after any exercise of this Warrant and in any event within three (3) Trading Days thereafter
(such date, the &ldquo;<U>Exercise Share Delivery Date</U>&rdquo;), the Company shall, at its expense (including the payment by it of
any applicable issue or stamp taxes), cause to be issued in the name of and delivered to the Holder, or as the Holder may direct, a certificate
or certificates evidencing the number of fully paid and non-assessable shares of Common Stock (which number shall be rounded down to the
nearest whole share in the event any fractional share may otherwise be issuable upon such exercise and the Company shall pay a cash adjustment
to the Holder in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price) to which the Holder
shall be entitled on such exercise, in such denominations as may be requested by the Holder, which certificate or certificates shall be
free of restrictive and trading legends (except for any such legends as may be required under the Securities Act). In lieu of delivering
physical certificates for the shares of Common Stock issuable upon any exercise of this Warrant, provided the Warrant Shares are not restricted
securities and the Company&rsquo;s transfer agent is participating in the Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;) Fast Automated
Securities Transfer program or a similar program, upon request of the Holder, the Company shall cause its transfer agent to electronically
transmit such shares of Common Stock issuable upon exercise of this Warrant to the Holder (or its designee), by crediting the account
of the Holder&rsquo;s (or such designee&rsquo;s) broker with DTC through its Deposit Withdrawal Agent Commission system (provided that
the same time periods herein as for stock certificates shall apply) as instructed by the Holder (or its designee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.   <U>Compensation
for Buy-In on Failure to Timely Deliver Exercise Shares</U>. In addition to any other rights available to the Holder, if the Company fails
to cause its transfer agent to transmit to the Holder Exercise Shares pursuant to an exercise on or before the Exercise Share Delivery
Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Exercise Shares which
the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (a) pay in cash to the Holder
the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Exercise Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation
was executed, and (b) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (a) of
the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure
to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3.   <U>Charges,
Taxes and Expenses</U>. Issuance of Exercise Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Exercise Shares, all of which taxes and expenses shall be paid by the Company, and
such Exercise Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that in the event Exercise Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto (the &ldquo;<U>Assignment Form</U>&rdquo;) duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.   <U>CERTAIN
ADJUSTMENT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1.   <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (a) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (b) subdivides outstanding shares of Common Stock into a larger number of shares, (c) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (d) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this <U>Section 5.1</U> shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2   <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to
the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the beneficial ownership
limitation provided for in <U>Section 10</U>, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the beneficial ownership limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3   <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (a) the Company effects any merger or consolidation of the Company
with or into another Person, (b) the Company effects any sale of all or substantially all of its assets in one or a series of related
transactions, (c) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders
of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (d) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into
or exchanged for other securities, cash or property (each, a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon the closing of
a Fundamental Transaction and payment of the exercise price therefore (including at the election of the Holder by cashless exercise),
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior
to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 10 on the
exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is
the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 10 on the exercise of this Warrant). For purposes of
any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based
on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company
shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be
received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental
Transaction the result of which is that in excess of 33% of the Company&rsquo;s outstanding equity shall be held by Persons differing
to those immediately prior to such Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the
Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the
date of the consummation of such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value this Warrant based
on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the final day of the Exercise Period, (B) an expected volatility equal to the greater of 100% and
the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the
sum of the price per share being offered in cash, if any, plus the value of any non- cash consideration, if any, being offered in such
Fundamental Transaction and (ii) the greater of (x) the last volume weighted average price immediately prior to the public announcement
of such Fundamental Transaction and (y) the last volume weighted average price immediately prior to the consummation of such Fundamental
Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the final day of the Exercise Period. The payment of the Black Scholes Value will be made by wire transfer of immediately
available funds within five Business Days of the Holder&rsquo;s election (or, if later, on the effective date of the Fundamental Transaction).
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in
accordance with the provisions of this 5.3 pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4   <U>Adjustment
to Exercise Price Upon Issuance of Common Stock</U>. If the Company shall, at any time after the Issue Date, issue or sell any shares
of Common Stock (other than in an Exempted Securities), whether directly or indirectly by way of Convertible Securities (&ldquo;<U>Additional
Shares of Common Stock</U>&rdquo;), without consideration or for consideration per share less than the Exercise Price in effect immediately
prior to such issuance or sale, then immediately upon such issuance or sale, the Exercise Price in effect immediately prior to such issuance
or sale shall be reduced (and in no event increased) to an Exercise Price equal to the consideration per share paid for such Additional
Shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5   <U>Calculations</U>.
All calculations under this <U>Section 5</U> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this <U>Section 5</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding at the close of the Trading
Day on or, if not applicable, most recently preceding, such given date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6   <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)    <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 5</U>, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring
such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)    <U>Notice
to Allow Exercise by Holder</U>. If (i) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock; (ii) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock; (iii) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights; (iv) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property;
or (v) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company;
then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register
of the Company, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a
record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the
mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. Subject to applicable law,
the Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event
triggering such notice. Notwithstanding the foregoing, the delivery of the notice described in this <U>Section 5.6</U> is not intended
to and shall not bestow upon the Holder any voting rights whatsoever with respect to outstanding unexercised Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.   <U>NO
IMPAIRMENT</U>. The Company will not, by amendment of the Articles of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and
in taking all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment. Without
limiting the generality of the foregoing, the Company (a) will not increase the par value of any shares of Common Stock receivable on
the exercise of this Warrant above the amount payable therefor on such exercise and (b) will take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of stock on the exercise of
this Warrant from time to time outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.   <U>NOTICES
OF RECORD DATE</U>. In the event of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)   any
taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock
of any class or any other securities or property, or to receive any other right;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)   any
capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any transfer of
all or substantially all the assets of the Company to or any consolidation or merger of the Company with or into any other Person or any
other Change of Control; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)   any
voluntary or involuntary dissolution, liquidation or winding-up of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then, and in each such event, the Company will
mail or cause to be mailed to the Holder a notice specifying (i) the date on which any such record is to be taken for the purpose of such
dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the date on which
any such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution, liquidation or winding-up is
anticipated to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock shall be entitled to
exchange their shares of Common Stock for securities or other property deliverable on such reorganization, reclassification, recapitalization,
transfer, consolidation, merger, dissolution, liquidation or winding-up. Such notice shall be mailed at least fifteen (15) days prior
to the date specified in such notice on which any such action is to be taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.   <U>RESERVATION
OF STOCK ISSUABLE ON EXERCISE OF WARRANT; REGULATORY COMPLIANCE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1.   <U>Reservation
of Stock Issuable on Exercise of Warrant</U>. The Company shall at all times while this Warrant shall be outstanding, reserve and keep
available out of its authorized but unissued Common Stock, such number of shares of Common Stock as shall from time to time be sufficient
to effect the exercise of all or any portion of the Warrant Shares (disregarding for this purpose any and all limitations of any kind
on such exercise). The Company shall, from time to time in accordance with the Delaware General Corporation Law, increase the authorized
number of shares of Common Stock or take other effective action if at any time the unissued number of authorized shares shall not be sufficient
to satisfy the Company&rsquo;s obligations under this <U>Section 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2.   <U>Regulatory
Compliance</U>. If any shares of Common Stock to be reserved for the purpose of exercise of the Warrant Shares require registration or
listing with or approval of any Governmental Authority, stock exchange or other regulatory body under any federal or state law or regulation
or otherwise before such shares may be validly issued or delivered upon exercise, the Company shall, at its sole cost and expense, in
good faith and as expeditiously as possible, secure such registration, listing or approval, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.   <U>DEFINITIONS</U>.
As used herein the following terms, unless the context otherwise requires, have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control
with, the Person specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Aggregate
Exercise Price</U></FONT>&rdquo; <FONT STYLE="font-size: 10pt">means, in connection with the exercise of this Warrant at any time, an
amount equal to the product obtained by multiplying (i) the Exercise Price times (ii) the number of shares of Common Stock for which this
Warrant is being exercised at such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Articles of Incorporation</U>&rdquo;
means the Company&rsquo;s Restated Articles of Incorporation as amended to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than a Saturday, Sunday or any other day on which banks are permitted or required to be closed in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Change of Control</U>&rdquo;
has the meaning set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means (i) the Company&rsquo;s Common Stock, $0.001 par value per share, and (ii) any other securities into which or for which any of the
securities described in clause (i) above have been converted or exchanged pursuant to a plan of recapitalization, reorganization, merger,
sale of assets or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Convertible Securities</U>&rdquo;
means any debt, equity or other securities that are, directly or indirectly, convertible into or exchangeable for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Period</U>&rdquo;
means the period commencing on the Issue Date and ending 11:59 P.M. (New York City time) on the date that is sixty (60) months from the
Issue Date or earlier closing of a Fundamental Transaction (other than a Fundamental Transaction of the type described in clause (d) of
the definition thereof resulting in the conversion into or exchange for another security of the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Price</U>&rdquo;
means $2.00 per share, as may be adjusted pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Shares</U>&rdquo;
means the shares of Common Stock for which this Warrant is then being exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fair Market Value</U>&rdquo;
means, with respect to any security or other property, the fair market value of such security or other property as determined by the Board
of Directors, acting in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Governmental Authority</U>&rdquo;
means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any
agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial,
taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the
European Union or the European Central Bank).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issue Date</U>&rdquo;
means November 17, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Note</U></FONT>&rdquo;
<FONT STYLE="font-size: 10pt">means the senior secured convertible promissory note issued by the Company to the Holder pursuant to the
Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Person</U></FONT>&rdquo;
<FONT STYLE="font-size: 10pt">means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means, as of any time of determination and with respect to any Person, any United States corporation, partnership, limited liability company
or limited liability partnership, all of the stock (or other equity interest) of every class of which, except directors&rsquo; qualifying
shares (or any equivalent), shall, at such time, be owned by such Person either directly or through Subsidiaries and of which such Person
or a Subsidiary shall have 100% control thereof, except directors&rsquo; qualifying shares. Unless the context otherwise clearly requires,
any reference to a &ldquo;Subsidiary&rdquo; is a reference to a Subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means whichever of the New York Stock Exchange, NYSE: Amex Exchange, or the Nasdaq Stock Market (including the Nasdaq Capital Market),
on which the Common Stock is listed or quoted for trading on the date in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, as of any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of one share of Common Stock trading in the ordinary course of
business on the applicable Trading Price for such date (or the nearest preceding date) on such Trading Market as reported by Bloomberg
Financial L.P.; (b) if the Common Stock is not then listed on a Trading Market and if the Common Stock is traded in the over-the-counter
market, as reported by the OTC Bulletin Board, the volume weighted average price of one share of Common Stock for such date (or the nearest
preceding date) on the OTC Bulletin Board, as reported by Bloomberg Financial L.P.; (c) if the Common Stock is not then listed or quoted
on the OTC Bulletin Board and if prices for the Common Stock is then reported in the &ldquo;Pink Sheets&rdquo; published by the Pink OTC
Markets Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price of one share
of Common Stock so reported, as reported by Bloomberg Financial L.P.; or (d) in all other cases, the fair market value of one share of
Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company (in
each case rounded to four decimal places).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Warrant
Shares</U></FONT>&rdquo; <FONT STYLE="font-size: 10pt">means collectively the shares of Common Stock of the Company issuable upon exercise
of the Warrant in accordance with its terms, as such number may be adjusted pursuant to the provisions thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.   <U>LIMITATION
ON BENEFICIAL OWNERSHIP</U>. Notwithstanding anything to the contrary contained herein, the Holder shall not be entitled to receive shares
of Common Stock or other securities (together with Common Stock, &ldquo;<U>Equity Interests</U>&rdquo;) upon exercise of this Warrant
to the extent (but only to the extent) that such exercise or receipt would cause the Holder Group to become, directly or indirectly, a
&ldquo;beneficial owner&rdquo; (within the meaning of Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder)
of a number of Equity Interests of a class that is registered under the Exchange Act which exceeds the Maximum Percentage (as defined
below) of the Equity Interests of such class that are outstanding at such time. Any purported delivery of Equity Interests in connection
with the exercise of the Warrant prior to the termination of this restriction in accordance herewith shall be void and have no effect
to the extent (but only to the extent) that such delivery would result in the Holder Group becoming the beneficial owner of more than
the Maximum Percentage of the Equity Interests of a class that is registered under the Exchange Act that is outstanding at such time.
If any delivery of Equity Interests owed to the Holder following exercise of this Warrant is not made, in whole or in part, as a result
of this limitation, the Company&rsquo;s obligation to make such delivery shall not be extinguished and the Company shall deliver such
Equity Interests as promptly as practicable after the Holder gives notice to the Company that such delivery would not result in such limitation
being triggered or upon termination of the restriction in accordance with the terms hereof. To the extent limitations contained in this
<U>Section 10</U> apply, the determination of whether this Warrant is exercisable and of which portion of this Warrant is exercisable
shall be the sole responsibility and in the sole determination of the Holder, and the submission of an Exercise Notice shall be deemed
to constitute the Holder&rsquo;s determination that the issuance of the full number of Warrant Shares requested in the Exercise Notice
is permitted hereunder, and neither the Company nor any Warrant agent shall have any obligation to verify or confirm the accuracy of such
determination. For purposes of this <U>Section 10</U>, (i) the term &ldquo;<U>Maximum Percentage</U>&rdquo; shall mean 4.99%; provided,
that if at any time after the date hereof the Holder Group beneficially owns in excess of 4.99% of any class of Equity Interests in the
Company that is registered under the Exchange Act (excluding any Equity Interests deemed beneficially owned by virtue of this Warrant
or the Note), then the Maximum Percentage shall automatically increase to 9.99% so long as the Holder Group owns in excess of 4.99% of
such class of Equity Interests (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon the Holder Group ceasing to
own in excess of 4.99% of such class of Equity Interests); and (ii) the term &ldquo;<U>Holder Group</U>&rdquo; shall mean the Holder plus
any other Person with which the Holder is considered to be part of a group under Section 13 of the Exchange Act or with which the Holder
otherwise files reports under Sections 13 and/or 16 of the Exchange Act. In determining the number of Equity Interests of a particular
class outstanding at any point in time, the Holder may rely on the number of outstanding Equity Interests of such class as reflected in
(x) the Company&rsquo;s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission, as the case may be, (y) a more recent public announcement by the Company or (z) a more recent notice by the Company or its
transfer agent to the Holder setting forth the number of Equity Interests of such class then outstanding. For any reason at any time,
upon written or oral request of the Holder, the Company shall, within one (1) Trading Day of such request, confirm orally and in writing
to the Holder the number of Equity Interests of any class then outstanding. The provisions of this <U>Section 10</U> shall be construed,
corrected and implemented in a manner so as to effectuate the intended beneficial ownership limitation herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.   <U>REGISTRATION
AND TRANSFER OF WARRANT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1.   <U>Registration
of Warrant</U>. The Company shall register and record transfers, exchanges, reissuances and cancellations of this Warrant, upon the records
to be maintained by the Company for that purpose, in the name of the record holder hereof from time to time. The Company may deem and
treat the registered holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to
the Holder, and for all other purposes, absent actual notice to the contrary. The Company shall be entitled to rely, and held harmless
in acting or refraining from acting in reliance upon, any notices, instructions or documents it believes in good faith to be from an authorized
representative of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2   <U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form of assignment (the &ldquo;<U>Assignment Notice</U>&rdquo;) attached hereto duly executed by the Holder
or its agent or attorney. The Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the
transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of the transferred Warrant under the 1933 Act. Upon such surrender, the Company shall execute and deliver
a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified
in such Assignment Notice, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the
purchase of Exercise Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3.   <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with <U>Section 11.2</U>, as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for this Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical
with this Warrant except as to the number of Exercise Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.   <U>LOSS,
THEFT, DESTRUCTION OR MUTILATION OF WARRANT</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Exercise Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.   <U>REMEDIES</U>.
The Company stipulates that the remedies at law of the Holder in the event of any default or threatened default by the Company in the
performance of or compliance with any of the terms of this Warrant are not and will not be adequate, and that such terms may be specifically
enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a violation of any of
the terms hereof or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.   <U>NO
RIGHTS AS A STOCKHOLDER</U>. Except as otherwise specifically provided herein, the Holder, solely in such Person&rsquo;s capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for
any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity
as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Exercise
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.   <U>NOTICES</U>.
All notices, requests, demands and other communications that are required or may be given pursuant to the terms of this Warrant shall
be in writing and shall be deemed delivered (i) on the date of delivery when delivered by hand on a Business Day during normal business
hours or, if delivered on a day that is not a Business Day or after normal business hours, then on the next Business Day, (ii) on the
date of transmission when sent by facsimile transmission or email during normal business hours on a Business Day with telephone confirmation
of receipt or, if transmitted on a day that is not a Business Day or after normal business hours, then on the next Business Day, or (iii)
on the second Business Day after the date of dispatch when sent by a reputable courier service that maintains records of receipt. The
addresses for notice shall be as set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.   <U>CONSENT
TO AMENDMENTS</U>. Any term of this Warrant may be amended, and the Company may take any action herein prohibited, or compliance therewith
may be waived, only if the Company shall have obtained the written consent (and not without such written consent) to such amendment, action
or waiver from the Holder. No course of dealing between the Company and the Holder nor any delay in exercising any rights hereunder shall
operate as a waiver of any rights of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.   <U>MISCELLANEOUS</U>.
In case any provision of this Warrant shall be invalid, illegal or unenforceable, or partially invalid, illegal or unenforceable, the
provision shall be enforced to the extent, if any, that it may legally be enforced and the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby. If any provision of this Warrant is found to conflict with
the Purchase Agreement, the provisions of this Warrant shall prevail. If any provision of this Warrant is found to conflict with the Note,
the provisions of the Note shall prevail. THIS WARRANT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND THE RIGHTS OF THE PARTIES
SHALL BE GOVERNED BY, THE INTERNAL LAW OF THE STATE OF NEVADA EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE LAW OF SUCH STATE THAT WOULD PERMIT
THE APPLICATION OF THE LAWS OF A JURISDICTION OTHER THAN SUCH STATE. The headings in this Warrant are for purposes of reference only,
and shall not limit or otherwise affect any of the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Remainder of Page Intentionally Left Blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its duly authorized officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated as of November [&#9679;], 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>ABVC BIOPHARMA, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="text-align: justify">Uttam Patil</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF SUBSCRIPTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be signed only on exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of Common Stock Purchase Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-size: 10pt">TO:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">ABVC BioPharma, Inc.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.   The
undersigned Holder of the attached Warrant hereby elects to exercise its purchase right under such Warrant to purchase shares of Common
Stock of ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), as follows (check one or more, as applicable):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">to exercise the Warrant to purchase __________ shares of Common Stock and to pay the Aggregate Exercise
Price therefor by wire transfer of United States funds to the account of the Company, which transfer has been made prior to or as of the
date of delivery of this Form of Subscription pursuant to the instructions of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">to exercise the Warrant with respect to ____________ shares of Common Stock pursuant to the net exercise
provisions specified in Section 2.3 of the Warrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.   In
exercising this Warrant, the undersigned Holder hereby confirms and acknowledges that the shares of Common Stock are being acquired solely
for the account of the undersigned and not as a nominee for any other party, and for investment, and that the undersigned shall not offer,
sell or otherwise dispose of any such shares of Common Stock except under circumstances that will not result in a violation of the Securities
Act or any state securities laws. The undersigned hereby further confirms and acknowledges that it is an &ldquo;accredited investor&rdquo;,
as that term is defined under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.   Please
issue a stock certificate or certificates representing the appropriate number of shares of Common Stock in the name of the undersigned
or in such other name(s) as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 8%">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%">&nbsp;</TD>
    <TD STYLE="width: 56%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>TIN:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 44%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 5%">Dated:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 25%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(Signature must conform exactly to name of </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Holder as specified on the face of the Warrant)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be signed only on transfer of Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For value received, the undersigned
hereby sells, assigns, and transfers unto ________________ the right represented by the within Warrant to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
shares of Common Stock of ABVC BioPharma, Inc., a Nevada corporation, to which the within Warrant relates, and appoints _________________
attorney to transfer such right on the books of ABVC BioPharma, Inc., with full power of substitution in the premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">[insert name of Holder]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 28%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 36%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Dated:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">[insert address of Holder]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signed in the presence of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ea188623ex10-4_abvcbio.htm
<DESCRIPTION>FIRST AMENDMENT TO SECURITY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXECUTION VERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FIRST AMENDMENT TO SECURITY AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This FIRST AMENDMENT TO SECURITY
AGREEMENT (the &ldquo;<B><U>Amendment</U></B>&rdquo;) is dated effective as of November 17, 2023 (the <B>&ldquo;<U>Amendment Effective
Date</U></B>&rdquo;), by and between <B>ABVC BioPharma, Inc.</B>, a Nevada corporation (the &ldquo;<B><U>Company</U></B>&rdquo;) and <B>Lind
Global Fund II LP</B> (&ldquo;<B><U>Lind</U></B>&rdquo; and together with the Company, the &ldquo;<B><U>Parties</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>the Company
and Lind entered into and executed that certain Security Agreement, dated as of February 23, 2023 (such Security Agreement, together with
all amendments, modifications, substitutions, or replacements thereof, collectively referred to as the <B>&ldquo;<U>Security Agreement</U></B>&rdquo;),
pursuant to which the Company granted a security interest in its assets to secure the obligations of the Company in respect of that certain
Promissory Note in the principal amount of $3,704,167 (the &ldquo;<B><U>Original Note</U></B>&rdquo;), issued by the Company to Lind pursuant
to the terms of that certain Securities Purchase Agreement, dated as of February 23, 2023 (the &ldquo;<B><U>February 2023 Purchase Agreement</U></B>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
wishes to issues to Lind and Lind wishes to accept an additional Promissory Note in a principal amount of up to $1,200,000 (the &ldquo;<B><U>New
Note</U></B>&rdquo;) and the Company and Lind wish to enter into a securities purchase agreement, dated as of the date hereof (the &ldquo;<B><U>New
Purchase Agreement</U></B>&rdquo;) to provide for the issuance of the New Note thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>in connection
with the issuance of the New Note, the Parties have agreed to amend the Security Agreement as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE, </B>in
consideration of the premises and the mutual covenants of the parties hereinafter expressed and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto, each intending to be legally bound, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <U>Recitals</U>. The recitations
set forth in the preamble of this Amendment are true and correct and incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <U>Capitalized Terms</U>.
All capitalized terms used in this Amendment shall have the same meaning ascribed to them in the Security Agreement, except as otherwise
specifically set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <U>Conflicts</U>. In the
event of any conflict or ambiguity by and between the terms and provisions of this Amendment and the terms and provisions of the Security
Agreement, the terms and provisions of this Amendment shall control, but only to the extent of any such conflict or ambiguity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. <U>Amendment to Security
Agreement</U>. The Security Agreement is hereby amended by deleting the definition of &ldquo;Obligations&rdquo; in Section 1 thereof and
replacing it with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;<U>Obligations</U>&rdquo; means,
collectively, (a) all debts, liabilities and obligations, present or future, direct or indirect, absolute or contingent, matured or unmatured,
at any time or from time to time due or accruing, due and owing by or otherwise payable by the Company or any Guarantor to the Secured
Party, in any currency, under, in connection with or pursuant to any Transaction Document (including, without limitation, this Agreement),
the New Purchase Agreement, the New Note, the February 2023 Purchase Agreement, the Original Note and any other Transaction Document which
are owed to Secured Party, and whether incurred by the Company or any Guarantor alone or jointly with another or others and whether as
principal, guarantor or surety and in whatever name or style and (b) all expenses, costs and charges incurred by or on behalf of the Secured
Party in connection with any Transaction Document (including this Agreement), the New Purchase Agreement, the New Note, the February 2023
Purchase Agreement, the Original Note and any other Transaction Document which are owed to Secured Party, or the Collateral, including
all legal fees, court costs, receiver&rsquo;s or agent&rsquo;s remuneration and other expenses of taking possession of, repairing, protecting,
insuring, preparing for disposition, realizing, collecting, selling, transferring, delivering or obtaining payment for the Collateral,
and of taking, defending or participating in any action or proceeding in connection with any of the foregoing matters or otherwise in
connection with the Secured Party&rsquo;s interest in any Collateral, whether or not directly relating to the enforcement of this Agreement
or any other Transaction Document, the New Purchase Agreement, the New Note, the February 2023 Purchase Agreement, the Original Note and
any other Transaction Document which are owed to Secured Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. <U>No Waiver</U>. Neither
this Amendment, nor shall Lind&rsquo;s agreement to accept the New Note, be deemed or construed in any manner as a waiver by Lind of any
claims, Proceedings, defaults, Events of Default, breaches or misrepresentations by Company under the Original Note, the February 2023
Purchase Agreement, any other Transaction Documents (as defined in the February 2023 Purchase Agreement), or any of Holder&rsquo;s rights
or remedies in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: justify; text-indent: 34.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6. <U>Not a Novation</U>.
This Amendment is a modification of the Security Agreement only and not a novation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: justify; text-indent: 34.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7. <U>Effect on Agreement
and Transaction Document</U>s. Except as expressly amended by this Amendment, all of the terms and provisions of the Security Agreement
and the Transaction Documents shall remain and continue in full force and effect after the execution of this Amendment, are hereby ratified
and confirmed, and incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. <U>Execution</U><B>. </B>This
Amendment may be executed in one or more counterparts, all of which taken together shall be deemed and considered one and the same Amendment.
In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &ldquo;.pdf&rsquo; format file or other
similar format file, such signature shall be deemed an original for all purposes and shall create a valid and binding obligation of the
party executing same with the same force and effect as if such facsimile or &ldquo;.pdf&rsquo; signature page was an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signatures on the following page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have duly executed this Amendment as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>LIND GLOBAL FUND II LP</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&#8239;</TD>
    <TD STYLE="text-align: justify; width: 35%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>ABVC BIOPHARMA, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: </TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>ea188623ex10-5_abvcbio.htm
<DESCRIPTION>FIRST AMENDMENT TO GUARANTOR SECURITY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXECUTION VERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FIRST AMENDMENT TO GUARANTOR SECURITY AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This FIRST AMENDMENT TO GUARANTOR
SECURITY AGREEMENT (the &ldquo;<B><U>Amendment</U></B>&rdquo;) is dated effective as of November 17, 2023 (the <B>&ldquo;<U>Amendment
Effective Date</U></B>&rdquo;), by and among <B>American BriVision Corporation</B>, a Delaware corporation (&ldquo;<B><U>American BriVision</U></B>&rdquo;),
<B>BioKey, Inc.</B>, a California corporation (&ldquo;<B><U>BioKey</U></B>&rdquo;), <B>BioLite Holding, Inc.</B>, a Nevada corporation
(&ldquo;<B><U>BioLite</U></B>&rdquo;), <B>BioLite BVI, Inc.</B>, a British Virgin Islands corporation (&ldquo;<B><U>BioLite BVI</U></B>,
and, collectively with American BriVision, BioKey and BioLite, the &ldquo;<B><U>Companies</U></B>&rdquo;, and each, individually, a &ldquo;<B><U>Company</U></B>&rdquo;)
and <B>Lind Global Fund II LP</B> (&ldquo;<B><U>Lind</U></B>&rdquo; and together with the Companies, the &ldquo;<B><U>Parties</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>the Companies
and Lind entered into and executed that certain Guarantor Security Agreement, dated as of February 23, 2023 (such Guarantor Security Agreement,
together with all amendments, modifications, substitutions, or replacements thereof, collectively referred to as the <B>&ldquo;<U>Security
Agreement</U></B>&rdquo;), pursuant to which each Company granted a security interest in its assets to secure the obligations of each
Company in respect of that certain Promissory Note in the principal amount of $3,704,167 (the &ldquo;<B><U>Original Note</U></B>&rdquo;),
issued by ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<B><U>Parent</U></B>&rdquo;) to Lind pursuant to the terms of that certain
Securities Purchase Agreement, dated as of February 23, 2023 (the &ldquo;<B><U>February 2023 Purchase Agreement</U></B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Parent
wishes to issues to Lind and Lind wishes to accept an additional Promissory Note in a principal amount of up to $1,200,000 (the &ldquo;<B><U>New
Note</U></B>&rdquo;) and the Parent and Lind wish to enter into a securities purchase agreement, dated as of the date hereof (the &ldquo;<B><U>New
Purchase Agreement</U></B>&rdquo;) to provide for the issuance of the New Note thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>in connection
with the issuance of the New Note, the Parties have agreed to amend the Security Agreement as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE, </B>in
consideration of the premises and the mutual covenants of the parties hereinafter expressed and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto, each intending to be legally bound, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <U>Recitals</U>. The recitations
set forth in the preamble of this Amendment are true and correct and incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <U>Capitalized Terms</U>.
All capitalized terms used in this Amendment shall have the same meaning ascribed to them in the Security Agreement, except as otherwise
specifically set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <U>Conflicts</U>. In the
event of any conflict or ambiguity by and between the terms and provisions of this Amendment and the terms and provisions of the Security
Agreement, the terms and provisions of this Amendment shall control, but only to the extent of any such conflict or ambiguity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. <U>Amendment to Security
Agreement</U>. The Security Agreement is hereby amended by deleting the definition of &ldquo;Obligations&rdquo; in Section 1 thereof and
replacing it with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;<U>Obligations</U>&rdquo; means,
collectively, (a) all debts, liabilities and obligations, present or future, direct or indirect, absolute or contingent, matured or unmatured,
at any time or from time to time due or accruing due and owing by or otherwise payable by the Parent or any Guarantor (including, without
limitation, any Company) to the Secured Party in any currency, under, in connection with or pursuant to the any Transaction Document (including,
without limitation, this Agreement), the New Purchase Agreement, the New Note, the February 2023 Purchase Agreement, the Original Note
and any other Transaction Document which are owed to Secured Party and whether incurred by the Parent or any Guarantor (including, without
limitation, any Company) alone or jointly with another or others and whether as principal, guarantor or surety and in whatever name or
style and (b) all expenses, costs and charges incurred by or on behalf of the Secured Party in connection with any Transaction Document
(including this Agreement), the New Purchase Agreement, the New Note, the February 2023 Purchase Agreement, the Original Note and any
other Transaction Document which are owed to Secured Party or the Collateral, including all legal fees, court costs, receiver&rsquo;s
or agent&rsquo;s remuneration and other expenses of taking possession of, repairing, protecting, insuring, preparing for disposition,
realizing, collecting, selling, transferring, delivering or obtaining payment for the Collateral, and of taking, defending or participating
in any action or proceeding in connection with any of the foregoing matters or otherwise in connection with the Secured Party&rsquo;s
interest in any Collateral, whether or not directly relating to the enforcement of this Agreement or any other Transaction Document, the
New Purchase Agreement, the New Note, the February 2023 Purchase Agreement, the Original Note and any other Transaction Document which
are owed to Secured Party..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. <U>No Waiver</U>. Neither
this Amendment, nor shall Lind&rsquo;s agreement to accept the New Note, be deemed or construed in any manner as a waiver by Lind of any
claims, Proceedings, defaults, Events of Default, breaches or misrepresentations by any Company under the Original Note, the February
2023 Purchase Agreement, any other Transaction Documents (as defined in the February 2023 Purchase Agreement), or any of Holder&rsquo;s
rights or remedies in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: justify; text-indent: 34.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6. <U>Not a Novation</U>.
This Amendment is a modification of the Security Agreement only and not a novation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: justify; text-indent: 34.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7. <U>Effect on Agreement
and Transaction Document</U>s. Except as expressly amended by this Amendment, all of the terms and provisions of the Security Agreement
and the Transaction Documents shall remain and continue in full force and effect after the execution of this Amendment, are hereby ratified
and confirmed, and incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. <U>Execution</U><B>. </B>This
Amendment may be executed in one or more counterparts, all of which taken together shall be deemed and considered one and the same Amendment.
In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &ldquo;.pdf&rsquo; format file or other
similar format file, such signature shall be deemed an original for all purposes and shall create a valid and binding obligation of the
party executing same with the same force and effect as if such facsimile or &ldquo;.pdf&rsquo; signature page was an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signatures on the following page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have duly executed this Amendment as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>LIND GLOBAL FUND II LP</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&#8239;</TD>
    <TD STYLE="text-align: justify; width: 35%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>AMERICAN BRIVISION CORPORATION</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: </TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>BIOKEY, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp; </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: </TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>BIOLITE HOLDING, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp; </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: </TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>BIOLITE BVI, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp; </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: </TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>ea188623ex10-6_abvcbio.htm
<DESCRIPTION>FIRST AMENDMENT TO GUARANTY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.6</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXECUTION VERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FIRST AMENDMENT TO GUARANTY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This FIRST AMENDMENT TO GUARANTY
AGREEMENT (the &ldquo;<B><U>Amendment</U></B>&rdquo;) is dated effective as of November 17, 2023 (the <B>&ldquo;<U>Amendment Effective
Date</U></B>&rdquo;), by and among <B>American BriVision Corporation</B>, a Delaware corporation (&ldquo;<B><U>American BriVision</U></B>&rdquo;),
<B>BioKey, Inc.</B>, a California corporation (&ldquo;<B><U>BioKey</U></B>&rdquo;), <B>BioLite Holding, Inc.</B>, a Nevada corporation
(&ldquo;<B><U>BioLite</U></B>&rdquo;), <B>BioLite BVI, Inc.</B>, a British Virgin Islands corporation (&ldquo;<B><U>BioLite BVI</U></B>,
and, collectively with American BriVision, BioKey and BioLite, the &ldquo;<B><U>Companies</U></B>&rdquo;, and each, individually, a &ldquo;<B><U>Company</U></B>&rdquo;)
and <B>Lind Global Fund II LP</B> (&ldquo;<B><U>Lind</U></B>&rdquo; and together with the Companies, the &ldquo;<B><U>Parties</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>the Companies
and Lind entered into and executed that certain Guaranty Agreement, dated as of February 23, 2023 (such Guaranty Agreement, together with
all amendments, modifications, substitutions, or replacements thereof, collectively referred to as the <B>&ldquo;<U>Guaranty</U></B>&rdquo;),
pursuant to which each Company, jointly and severally guaranteed the obligations of ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<B><U>Parent</U></B>&rdquo;)
in respect of that certain Promissory Note in the principal amount of $3,704,167 (the &ldquo;<B><U>Original Note</U></B>&rdquo;), issued
by the Parent to Lind pursuant to the terms of that certain Securities Purchase Agreement, dated as of February 23, 2023 (the &ldquo;<B><U>February
2023 Purchase Agreement</U></B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Parent
wishes to issues to Lind and Lind wishes to accept an additional Promissory Note in a principal amount of up to $1,200,000 (the &ldquo;<B><U>New
Note</U></B>&rdquo;) and the Parent and Lind wish to enter into a securities purchase agreement, dated as of the date hereof (the &ldquo;<B><U>New
Purchase Agreement</U></B>&rdquo;) to provide for the issuance of the New Note thereunder;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>in connection
with the issuance of the New Note, the Parties have agreed to amend the Guaranty as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE, </B>in
consideration of the premises and the mutual covenants of the parties hereinafter expressed and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto, each intending to be legally bound, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <U>Recitals</U>. The recitations
set forth in the preamble of this Amendment are true and correct and incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <U>Capitalized Terms</U>.
All capitalized terms used in this Amendment shall have the same meaning ascribed to them in the Guaranty, except as otherwise specifically
set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <U>Conflicts</U>. In the
event of any conflict or ambiguity by and between the terms and provisions of this Amendment and the terms and provisions of the Guaranty,
the terms and provisions of this Amendment shall control, but only to the extent of any such conflict or ambiguity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. <U>Amendment to Guaranty</U>.
The Guaranty is hereby amended by deleting the definition of &ldquo;Obligations&rdquo; in Section 1 thereof and replacing it with the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The term (a) &ldquo;Obligations&rdquo;
means, collectively, all debts, liabilities and obligations (including, without limitation, any expenses, costs and charges incurred by
or on behalf of the Lender in connection with any Transaction Document), present or future, direct or indirect, absolute or contingent,
matured or unmatured, at any time or from time to time due or accruing due and owing by or otherwise payable by the Borrower, the Guarantors,
or any other &ldquo;Guarantor&rdquo; (as such term is defined in the Borrower Security Agreement) (the &ldquo;Other Guarantors&rdquo;)
to the Lender in any currency, under, in connection with or pursuant to any Transaction Document (including, without limitation, this
Guaranty), and whether incurred by the Borrower, any Guarantor or any Other Guarantor alone or jointly with another or others and whether
as principal, guarantor or surety and in whatever name or style; and (b) &ldquo;Transaction Documents&rdquo; means, collectively, this
Guaranty and the &ldquo;Transaction Documents&rdquo; as defined in the SPA and the New Purchase Agreement. All other capitalized terms
used herein without definition shall have the respective meanings provided therefor in the SPA and the New Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. <U>No Waiver</U>. Neither
this Amendment, nor shall Lind&rsquo;s agreement to accept the New Note, be deemed or construed in any manner as a waiver by Lind of any
claims, Proceedings, defaults, Events of Default, breaches or misrepresentations by any Company under the February 2023 Purchase Agreement
and the New Purchase Agreement, any other Transaction Documents (as defined in the February 2023 Purchase Agreement and the New Purchase
Agreement), or any of Holder&rsquo;s rights or remedies in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: justify; text-indent: 34.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6. <U>Not a Novation</U>.
This Amendment is a modification of the Guaranty only and not a novation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: justify; text-indent: 34.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7. <U>Effect on Agreement
and Transaction Document</U>s. Except as expressly amended by this Amendment, all of the terms and provisions of the Guaranty and the
Transaction Documents shall remain and continue in full force and effect after the execution of this Amendment, are hereby ratified and
confirmed, and incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. <U>Execution</U><B>. </B>This
Amendment may be executed in one or more counterparts, all of which taken together shall be deemed and considered one and the same Amendment.
In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &ldquo;.pdf&rsquo; format file or other
similar format file, such signature shall be deemed an original for all purposes and shall create a valid and binding obligation of the
party executing same with the same force and effect as if such facsimile or &ldquo;.pdf&rsquo; signature page was an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signatures on the following page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have duly executed this Amendment as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>LIND GLOBAL FUND II LP</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&#8239;</TD>
    <TD STYLE="text-align: justify; width: 35%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>AMERICAN BRIVISION CORPORATION</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: </TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>BIOKEY, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp; </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: </TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>BIOLITE HOLDING, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp; </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: </TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>BIOLITE BVI, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp; </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: </TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>abvc-20231120.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /aIps7xRiXhun8uMb3AsOa2PicPtypV1eYkxvG99HXkqvyIo1FuC7SnRoWAmURsL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ABVC="http://abvcpharma.com/20231120" elementFormDefault="qualified" targetNamespace="http://abvcpharma.com/20231120">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://abvcpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20231120_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20231120_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>abvc-20231120_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>abvc-20231120_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abvcpharma.com/role/Cover" xlink:href="abvc-20231120.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abvcpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139882568160368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 20,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0014658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44370 Old Warm Springs Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">668-0881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>ea188623-8k_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abvc-20231120.xsd" xlink:type="simple"/>
    <context id="AsOf2023-11-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-11-20</startDate>
            <endDate>2023-11-20</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-11-20">0001173313</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AsOf2023-11-20">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="AsOf2023-11-20">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-11-20">2023-11-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-11-20">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-11-20">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-11-20">001-40700</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-11-20">26-0014658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-11-20">44370 Old Warm Springs Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-11-20">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-11-20">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-11-20">94538</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-11-20">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-11-20">668-0881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-11-20">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-11-20">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-11-20">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-11-20">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2023-11-20">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2023-11-20">ABVC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2023-11-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-11-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MQ$-T5R8AA:Y/!   A!   !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R=
MF&]OZC84QK^*E4W3)K5-',*?=H $W'87W5O*2M=*F_;") :L)G%F.]!^^QT'
MFK![PPG:BY8DY#SYY?CX.3;]G52O>L.Y(6])G.J!LS$FNW%='6YXPO25S'@*
MWZRD2IB!4[5V=:8XBXJ@)'9]S^NX"1.I,^P7U^9JV)>YB47*YXKH/$F8>A_S
M6.X&#G4^+CR*]<;8"^ZPG[$U7W#S1S97<.:6*I%(>*J%3(GBJX$SHC=C/[ !
MQ1W/@N_TT3&QK[*4\M6>3*.!XUDB'O/06 D&'UL^X7%LE8#CGX.H4S[3!AX?
M?ZC?%2\/+[-DFD]D_"(BLQDX/8=$?,7RV#S*W6=^>*&VU0MEK(O_9+>_-P@<
M$N;:R.00# 2)2/>?[.V0B., >B+ /P3X!??^007E)V;8L*_DCBA[-ZC9@^)5
MBVB $ZD=E851\*V .#.<R"U7?=> E+W@AH>P\3[,/Q$VD]LKXGL7\.>W_AON
M D&)X9<8?J'7PC#(7Z.E-@H&ZN\ZHKU"4*]@J_=&9RSD P?*4W.UY<[PIQ]H
MQ_L5X6N5?"U,??A)ACG4HB%/[QFO@\/#>Y=?$(B@A A0E1$01 7%7<S6=11X
M_(K%FB,<[9*C?5XRYEP)&9';-")0?+5YP97*,FJJHTZ)UD$%;U,CS#NY$S$G
MLSQ9UM<VKN%Y]#+PNIZ'\'1+GNXY/(]\+6QE0\YF+*E-%*XS&C]/R'CZ,/\\
M>KP?79#I;'*%X/5*O-XY>!,83,5B,DTC_D:^\/<Z0%S)@ZS1;JM%L5&\+K&N
MS\%Z8F]D&@&;6(F0%29^>DQQ1;]S"8!!I]U#\*A7F:9W#N T#:7*I"K8+LC"
MP"0@4I&)S"&AD%<9U8YU@_KL&8,\<G9Z#N0HBL /]<7' ?D*]Y&'M)X,EPR"
M5M<C#W%$7IA*R")3(EUK,HZW$5:.M&H#%'7Q[Y@G]@PR^B1W:2TO+G>G>")3
M@Z%5'8#B'OXM6CG:<R6W(@WK\XEK3D886M47*&[LWZ+-I38PG?\4V>D2Q!6O
M@W8+G2I5KZ"XQ1<C.((%XVD47*!-,2.F56>@N*U_E2'D9+Z1*=8:&D0ZG=ZE
MU^M1C*CJ#10W]1<EC.$I)"9)\O1@<;J6"A=J:NRTZ@<4M_&%C$4H#,QJ<@_E
MK02+:WEPE4:>JA%0W+?GBE^&D!X.\VN__H(E$*P4'U:K$^.'ZS61^54+\'&3
M_HYLJG4.9$V #;*-@)7]^[A7/PD#BR"Y(M3_>?D+6? PAWJK;>T-2K8^H?<N
MC Q?+TC&%-FR..?D1^\*FBK)X'7UABD4^V@C@%OVDV*1+;_%>[*4M<77(&"7
M2AA)9?@^;LX?&2.W;^&&I6M^<NW6(#0;+3Z-?L>8*J?WSW+ZVX2KM<W2;Z!@
M-M9!,I;6C^W_W!.X1WM*NS^_9_:)FL1\!4+>51=<6^VWO/L3([-BF[F4!C:M
MQ>&&,Y@+]@;X?B6E^3BQ.]?RAX?AOU!+ P04    " #$0W17GZ ;\+$"  #B
M#   #0   'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S
M85^56'8$>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2
MNMW0HW/-^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[
M=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2Q
MQ'DJ?$,78&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>X
MU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_P
MZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8Q
MA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R
M]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.
MRW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV0
M3NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_
MAOMHD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X
M87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%
MZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[
MC>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS
M/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " #$
M0W17EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0
M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I
M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE
M/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6
MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#
M!!0    ( ,1#=%>JQ"(6,P$  "("   /    >&PO=V]R:V)O;VLN>&ULC5'1
M;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<
M7187XM.!Z)1\>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IE
ML]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<
M9":)-5U>B/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1RE
MW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B
M]1!DZ)'!=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@
M?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " #$
M0W17)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
MM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)
M3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8
M,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):B
MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    " #$0W17!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,1#=%<XE,05
M[0   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( ,1#=%>97)PC$ 8  )PG   3              "  <L!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ Q$-T5R8AA:Y/!   A!
M !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( ,1#=%>?H!OPL0(  .(,   -              "  9$,  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ Q$-T5Y>*NQS     $P(   L
M         ( !;0\  %]R96QS+RYR96QS4$L! A0#%     @ Q$-T5ZK$(A8S
M 0  (@(   \              ( !5A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( ,1#=%<D'INBK0   /@!   :              "  ;81  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,1#=%=ED'F2&0$
M ,\#   3              "  9L2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  .43      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea188623-8k_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abvcpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abvc-20231120.xsd</File>
    <File>abvc-20231120_lab.xml</File>
    <File>abvc-20231120_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea188623-8k_abvcbio.htm">ea188623-8k_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea188623-8k_abvcbio.htm": {
   "nsprefix": "ABVC",
   "nsuri": "http://abvcpharma.com/20231120",
   "dts": {
    "schema": {
     "local": [
      "abvc-20231120.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20231120_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20231120_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea188623-8k_abvcbio.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://abvcpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2023-11-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea188623-8k_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-11-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea188623-8k_abvcbio.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001213900-23-088524-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-088524-xbrl.zip
M4$L#!!0    ( ,1#=%=NT"<0)@,  .D+   1    86)V8RTR,#(S,3$R,"YX
M<V2U5MMRVC 0?>],_T'UNRT,DZ802(:22<H,:3+0T/2I(V0!&F3)D60@?U_)
M-RX& K3UD[PZY^RN=E=V\V89,C G4E'!6X[O51Q .!8!Y9.6\SQPVX-.M^N
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M0'R&6&,7)01?)<\L)95/!%6>8\ CA2)'?';HL8<S][*8U+P]]Q2O[ @1]Y6
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MXLD<H%\$_G5\Q[C+$I=Z9$2M(2/_UO*:5B0NGIO",RB/\(P1?U:\VC++M,.
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MI [2PFMN#=2E=A&JJ<@$R.;!T2Z>Y@%]A2:Q%"R"-5,[$<P;H>D1P<(&B*_
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MX.:>/255P8K>[-AQ-E6T1#NZZTA:24XVM;4?0!*4$(, #P!*UO[ZVV\STS,
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M5PPB\#LJ9L92</L=U0]K%P+C]L1$+:A@!I_%5*[YR1+"Y!"N5Q)8Q$CO)T%
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M!:X8_RF4^0TUQF!W"SE.TIDEH.!.#JJ!3J?39ONT>(#62C4>- S!MC39-9_
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MJN&0G:E4Y6#]'I=U;=A^72N7=KAQN;3#QUS:UR>R?VXN[7E'+NUJ>/'SR>D
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M0*O;^A@&ZA6M;M>,AX82P*=I8)TC^E2W_1Y^>-([/FBWL8@K:/4Z??S[^'2
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M_:.#@\')V.L95;*UO=VOK_RQ?OB 'FZ/^);MDV_B$*HC=$<^]C<^1H,DZ79
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ML!11$DD!J!UP[S]L*7D,@C[I*XR5":B ,T(>8#8AR"A9:5&.]ZHE,-,,5%>
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M&FA6E5)LB4\V,$=B7U0P1M];(*4N^*K5 EW5+)\':?QO-\?J%>!&)D%.>,B
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M(T_:X> ^5G4Y*.BF,VI'-Y!QM(SX4Z[Q"F)J+G\21[3@<!1Y5LU9IM:.YDT
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M\+Y,];Q&!C?%]"!<+75(ND*T7S$+2X'-T/7,9J;4]X+Q+<KE%'H:GX(E2Z'
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M661MR?DU0 HM7'S7<>)XC19PC1&A(\^H[2"X7.=^2\IDFBV654OH9 UN4KP
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M2?Q5FL,'+<,DTEN73V+I*_Y+ OIF[C@$H*/0BN1:)#FCS '>K&W5M4!N>Y(
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MMI6^G=!4K,L24==9;-MH]L3@Y4!<&,%D0]]JZY=FJ>"%R*4IJ=6//4KY3L&
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MH_;)2P'V1Y:E?+*A2C]Z3AUR1]DKH7HK2CERPXFL%X@N4*U9@BK $D5_60I
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MQ,3Z6:B3AQ00,N+.$ DFK4J]=S=(- >I3*F0/?LQ)UC$&\RY'D;9Y$*R:[:
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M-&*-+\!*2>SECZG"-'_  <LBSB_$(]UNV:4_Q0"0!7.!32]V"[1925M&C#7
M?[@@,;#=LPR$!(A+M(! '!<Z_WP"/R6 (KKJQ3[A;&AZ R$P\5'&*>AO%9Y
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MF[%?7*_(=_C,DKPP-3<U,I-C-2INRTU!GE'!B:2FCI;R7?/N$=^6[:NYFZJ
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M'97SY=JD?#D!A-@YP)+80TZ#$Y:X2%\@3T88@G%V37Q@=:<9MVOH(#>F7,Y
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M=MA3L$HIO6G74S,REC85>_]?'AZRX4OQ=X\P=W]6,!B=O^U=_-(+V&!XO/F
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M=//RA?E*[8AWFS.LRP#GJ5:QQ_P,N$_ P Y;@SY* E*'5BGE=VS_YV3_A<9
M,QMZ0)LA*\!#J0XA&=LBA2(6*94:Q(LBDHG,:ZH#B_U%NY=/:2!H+RW:8?MY
M XM&KM=L:XOT9+J8W]A"!5>_7:FR/W=>@7+NQU;T<W_S:45K7M(7FB/7&69
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M.#8R,V5X,3 M-E]A8G9C8FEO+FAT;>U<;5/;2!+^[BK_AUEN-Y54"6,@+[O
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MJ 8\%0$382C\5%X(QC5+0C9(+L3,$XKMOG'87G-OWY!%15C*);*LFZ^NUTZ
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M,3(P7VQA8BYX;6Q02P$"% ,4    " #$0W17(XM:E58'  #95P  %0
M        @ &%#@  86)V8RTR,#(S,3$R,%]P<F4N>&UL4$L! A0#%     @
MQ$-T5PW-3]G0&0  >8D  !<              ( !#A8  &5A,3@X-C(S+3AK
M7V%B=F-B:6\N:'1M4$L! A0#%     @ Q$-T5Z_A,Z[CEP  ^6X# !H
M         ( !$S   &5A,3@X-C(S97@Q,"TQ7V%B=F-B:6\N:'1M4$L! A0#
M%     @ Q$-T5]);E05970  [BD" !H              ( !+L@  &5A,3@X
M-C(S97@Q,"TR7V%B=F-B:6\N:'1M4$L! A0#%     @ Q$-T5R/Y_I&^10
M)F$! !H              ( !OR4! &5A,3@X-C(S97@Q,"TS7V%B=F-B:6\N
M:'1M4$L! A0#%     @ Q$-T5SCFGGRZ#   M3D  !H              ( !
MM6L! &5A,3@X-C(S97@Q,"TT7V%B=F-B:6\N:'1M4$L! A0#%     @ Q$-T
M5\CPN@3"#0  T4D  !H              ( !IW@! &5A,3@X-C(S97@Q,"TU
M7V%B=F-B:6\N:'1M4$L! A0#%     @ Q$-T5Y9L&^_\#   ^D4  !H
M         ( !H88! &5A,3@X-C(S97@Q,"TV7V%B=F-B:6\N:'1M4$L%!@
0   *  H N@(  -63 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
